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Summary 100 
Schizophrenia and bipolar disorder are two distinct diagnoses that share symptomology. 101 
Understanding the genetic factors contributing to the shared and disorder-specific symptoms will 102 
be crucial for improving diagnosis and treatment. In genetic data consisting of 53,555 cases 103 
(20,129 BD, 33,426 SCZ) and 54,065 controls, we identified 114 genome-wide significant loci 104 
implicating synaptic and neuronal pathways shared between disorders. Comparing SCZ to BD 105 
(23,585 SCZ, 15,270 BD) identified four genomic regions including one with disorder-106 
independent causal variants and potassium ion response genes as contributing to differences in 107 
biology between the disorders. Polygenic risk score (PRS) analyses identified several significant 108 
correlations within case-only phenotypes including SCZ PRS with psychotic features and age of 109 
onset in BD. For the first time, we discover specific loci that distinguish between BD and SCZ and 110 
identify polygenic components underlying multiple symptom dimensions. These results point to 111 
the utility of genetics to inform symptomology and potentially treatment. 112 
 113 
 114 
Introduction 115 
Bipolar disorder (BD) and schizophrenia (SCZ) are severe psychiatric disorders and among the 116 
leading causes of disability worldwide(Whiteford et al., 2013). Both disorders have significant 117 
genetic components with heritability estimates ranging from 60-80%(Nöthen et al., 2010). Recent 118 
genetic and epidemiological studies have demonstrated substantial overlap between these two 119 
disorders with a genetic correlation from common variation near 0.6-0.7(Cross-Disorder Group of 120 
the Psychiatric Genomics Consortium, 2013) and high relative risks (RR) among relatives of both 121 
BD and SCZ patients (RRs for parent/offspring: BD/BD: 6.4, BD/SCZ: 2.4; SCZ/BD: 5.2, 122 
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SCZ/SCZ: 9.9)(Lichtenstein et al., 2009). Despite shared genetics and symptomology, the current 123 
diagnostic systems(“Diagnostic and Statistical Manual of Mental Disorders | DSM Library,” 124 
n.d.),(“WHO | International Classification of Diseases,” n.d.) adhere to historical distinctions from 125 
the late 19th century and represent BD and SCZ as independent categorical entities differentiated 126 
on the basis of their clinical presentation, with BD characterized by predominant mood symptoms, 127 
mood-congruent delusions and an episodic disease course and SCZ considered a prototypical 128 
psychotic disorder. Identifying genetic components contributing to both disorders provides insight 129 
into the biology underlying the shared symptoms of the disorders. 130 
While the shared genetic component is substantial, studies to date have also implicated genetic 131 
architecture differences between these two disorders(Curtis et al., 2011; Ruderfer et al., 2014). A 132 
polygenic risk score created from a case only SCZ vs BD genome-wide association study (GWAS) 133 
significantly correlated with SCZ or BD diagnosis in an independent sample(Ruderfer et al., 2014), 134 
providing the first evidence that differences between the disorders also have a genetic basis. An 135 
enrichment of rare, moderate to highly penetrant copy number variants (CNVs) and de novo CNVs 136 
are seen in SCZ patients(CNV and Schizophrenia Working Groups of the Psychiatric Genomics 137 
Consortium, 2017; Gulsuner and McClellan, 2015; Kirov et al., 2012; Stone et al., 2008; 138 
Szatkiewicz et al., 2014), while, the involvement of CNVs in BD is less clear(Green et al., 2016). 139 
Although the role of de novo single nucleotide variants in BD and SCZ has been investigated in 140 
only a handful of studies, enrichment in pathways associated with the postsynaptic density has 141 
been reported for SCZ, but not BD(Fromer et al., 2014; Kataoka et al., 2016). Identifying disorder-142 
specific variants and quantifying the contribution of genetic variation to specific symptom 143 
dimensions remain important open questions. Characterizing these genetic differences will 144 
facilitate an understanding of the dimensions of the disorders instead of the dichotomous diagnosis. 145 
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For example, we have shown that SCZ patients with greater manic symptoms have higher 146 
polygenic risk for BD(Ruderfer et al., 2014). These findings demonstrate shared genetic 147 
underpinnings for symptoms across disorders and may enable us to characterize patients by genetic 148 
liability to symptom dimensions thereby informing disease course and treatment. 149 
Here, we utilize large collections of genotyped samples for BD and SCZ along with clinically-150 
relevant measures identifying 28 subphenotypes to address three questions: 1) Are there specific 151 
variants, genes or pathways that are either shared by, or differentiate BD and SCZ? 2) Are the 152 
shared symptoms between these disorders driven by the same underlying genetic profiles? and 3) 153 
Can we demonstrate independent genetic signatures for subphenotypes within these disorders? 154 
 155 
Results 156 
 157 
Shared genetic contribution to BD and SCZ 158 
We performed association analysis of BD and SCZ combined into a single phenotype, totaling 159 
53,555 cases (20,129 BD, 33,426 SCZ) and 54,065 controls on 15.5 million SNP allele dosages 160 
imputed from 1000 genomes phase 3(The 1000 Genomes Project Consortium, 2015). Logistic 161 
regression was performed controlling for 13 principal components of ancestry, study sites and 162 
genotyping platform. We identified 11,231 SNPs with p-value below our genome-wide 163 
significance (GWS) threshold of 5x10-8. After grouping SNPs in linkage disequilibrium with each 164 
other (r2 > 0.2), 114 genomic risk loci remained. For the most significant variant in each of the 114 165 
GWS loci, we performed conditional analysis with any GWS hit within 1Mb of the extent of the 166 
locus from the previously performed single disease GWAS of SCZ(Schizophrenia Working Group 167 
of the Psychiatric Genomics Consortium, 2014) and BD(Stahl et al., 2017) and identified 32 loci 168 
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that were independently significant defined strictly as no single disease locus within 1Mb or a 169 
GWS p-value after conditional analysis (Supplementary Table 1). We further performed gene-set 170 
based tests using MAGMA(Leeuw et al., 2015) across 10,891 curated pathways(Watanabe et al., 171 
2017) and identified 8 pathways surpassing Bonferroni correction (p < 4.6x10-6) with all but one 172 
pathway implicating synaptic and neuronal biology (Supplementary Table 2a). Establishing 173 
independent controls (see Methods) allowed us to perform disorder-specific GWAS in 20,129 BD 174 
cases vs 21,524 BD controls and 33,426 SCZ cases and 32,541 SCZ controls. Using these results, 175 
we compared effect sizes of these 114 loci across each disorder independently showing the subsets 176 
of variants that had larger effects in SCZ compared to BD and vice versa (Figure 1a). 177 
 178 
Differentiating genetic contribution to BD and SCZ 179 
To identify loci with divergent effects on BD and SCZ, we performed an association analysis 180 
comparing 23,585 SCZ cases with 15,270 BD cases matched for shared ancestry and genotyping 181 
platform (see Methods, Figure 1b, Table 1). Two genome-wide significant loci were identified, the 182 
most significant of which was rs56355601 located on chromosome 1 at position 173,811,455 183 
within an intron of DARS2 (Supplementary Figure 1). The second most significant locus was 184 
rs200005157, a four base-pair insertion/deletion, on chromosome 20 at position 47638976 in an 185 
intron of ARFGEF2 (Supplementary Figure 2). For both variants, the minor allele frequency was 186 
higher in BD cases than SCZ cases and disease-specific GWAS showed opposite directions of 187 
effect when compared to controls. We sought to identify additional disease-specific loci by 188 
comprehensively incorporating expression information with association results to perform fine-189 
mapping and identify novel variants(Gamazon et al., 2015; Giambartolomei et al., 2014; Gusev et 190 
al., 2016; He et al., 2013). Here, we applied the summary-data-based Mendelian randomization 191 
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(SMR) method(Zhu et al., 2016) (see Methods) utilizing the cis-QTLs derived from peripheral 192 
blood(Westra et al., 2013), human dorsolateral prefrontal cortex (DLPFC)(Fromer et al., 2016) 193 
from the Common Mind Consortium and 11 brain regions from the GTEx consortium(Consortium, 194 
2015). We identified one SNP-probe combination that surpassed the threshold for genome-wide 195 
significance in blood but was also the most significant finding in brain. We found that SNP 196 
rs4793172 in gene DCAKD is associated with SCZ vs BD analysis (pGWAS = 2.8x10
-6) and is an 197 
eQTL for probe ILMN 1811648 (peQTL = 2.9x10
-168), resulting in pSMR = 4.1x10
-6 in blood (peQTL 198 
= 2.9x10-25, pSMR = 2.0x10
-5 in DLFC, and peQTL = 4.6x10
-15, pSMR = 6.0x10
-5 in GTEx cerebellar 199 
hemisphere) (Supplementary Table 3, Supplementary Figure 3) and shows no evidence of 200 
heterogeneity (pHET =0.66) which implies only a single causal variant in the locus. 201 
In an effort to prioritize genes for the two GWS loci from the GWAS, we performed fine-202 
mapping(Benner et al., 2016) using an LD map derived from a majority of the control samples. 203 
We then performed SMR on each of the variants with causal probability greater than 1% using all 204 
eQTLs from the CommonMind Consortium DLPFC reference. All the most likely causal variants 205 
were shown to most significantly regulate the same gene suggesting CSE1L is the most likely 206 
relevant gene on chromosome 20 (rs200005157: causal probability=0.21, pGWAS=2.4x10
-8, peQTL 207 
3x10-8, pSMR=8.5x10
-5, pHET=0.34). For the locus on chromosome 1, SLC9C2 is the most 208 
significantly regulated gene. However, a highly significant heterogeneity test indicates a complex 209 
genetic architecture making it difficult to infer a causal role for the associated SNP. Therefore, 210 
DARS2 presents as the most likely relevant gene on chromosome 1 (rs56355601: pGWAS=5.6x10
-9, 211 
causal probability=0.079, peQTL 7.4x10
-13, pSMR=6.17x10
-6, pHET=0.03). We note however, that in 212 
both cases there are less associated variants that are stronger eQTLs for these genes complicating 213 
a straightforward causal interpretation. Finally, using the same gene-set test used for the combined 214 
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analysis GO biological process “response to potassium ion” (p=1.6x10-6) was the only pathway 215 
surpassing our Bonferroni corrected significance threshold (Supplementary Table 2b). 216 
 217 
Regional joint association 218 
We expanded our efforts to identify disorder-specific genomic regions by jointly analyzing 219 
independent GWAS results from BD and SCZ(Pickrell et al., 2016). The genome was split into 220 
1,703 previously defined approximately LD independent regions(Berisa and Pickrell, 2015). 221 
Thirteen percent, or 223 regions, had a posterior probability greater than 0.5 of having a causal 222 
variant for at least one disorder. Of these, 132 best fit the model of a shared causal variant 223 
influencing both BD and SCZ, 88 were most likely specific to SCZ, 3 demonstrated evidence of 224 
two independent variants (with one impacting each of the two disorders) and none were BD-225 
specific. Of note, this approach calculates a prior probability that any given region is disease-226 
specific and from these data the probability of having a BD specific region was 0.1% compared to 227 
15% for SCZ, likely a result of increased power from the larger SCZ sample size and/or a 228 
difference in genetic architecture between these disorders. 229 
The 114 GWS SNPs from the combined BD and SCZ GWAS localized into 99 independent 230 
regions (13 regions had multiple GWS SNPs), of which 78 (79%) were shared with a posterior 231 
probability of greater than 0.5. Sixty regions had at least one GWS SNP in the independent SCZ 232 
GWAS, of which 30 (50%) are shared and 8 regions contained a GWS SNP in the independent 233 
BD GWAS, of which 6 (75%) are shared using the same definition. For the three regions showing 234 
evidence for independent variants, two had highly non-overlapping association signals in the same 235 
region stemming from independent variants. The third, on chromosome 19 presented a different 236 
scenario where association signals were overlapping. The most significant variant in BD was 237 
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rs111444407 (chr19:19358207, p = 8.67x10-10) and for SCZ was rs2315283 (chr19:19480575, 238 
p=4.41x10-7). After conditioning on the most significant variant in the other disorder, the 239 
association signals of the most significant variant in BD and SCZ were largely unchanged (BD 240 
rs111444407 =1.3x10-9, SCZ rs2315283 p=6.7x10-5). We further calculated the probability of each 241 
variant in the region being causal for both BD and SCZ(Benner et al., 2016) and found no 242 
correlation (r= -0.00016). The most significant variants had the highest posterior probability of 243 
being causal (SCZ: rs2315283, prob = 0.02, BD: rs111444407, prob = 0.16). Both variants most 244 
significantly regulate the expression of GATAD2A in brain(Fromer et al., 2016) but in opposite 245 
directions (rs111444407 peQTL = 6x10
-15, beta = 0.105; rs2315283 peQTL = 1.5x10
-28, beta = -0.11).  246 
 247 
Regional SNP-heritability estimation 248 
Across the genome, regional SNP-heritabilities (h2snp) were estimated separately for SCZ and 249 
BD(Shi et al., 2016) and were found to be moderately correlated (r=0.25). We next defined risk 250 
regions as those containing the most associated SNP for each GWS locus. In total, there were 101 251 
SCZ risk regions from the 105 autosomal GWS loci reported previously(Schizophrenia Working 252 
Group of the Psychiatric Genomics Consortium, 2014) and 29 BD risk regions from 30 GWS loci 253 
reported previously(Stahl et al., 2017). Ten regions were risk regions for both BD and SCZ 254 
comprising 33% of BD risk regions and 10% of SCZ risk regions. We further stratified regional 255 
h2snp by whether a region was a risk region in one disorder, none or both (Supplementary Figure 256 
4). Since the discovery data for the regions overlapped with the data used for the heritability 257 
estimation, we expected within-disorder analyses to show significant results. In risk regions 258 
specific to SCZ (n=91) there was a significant increase in regional h2snp in SCZ, as expected (p = 259 
1.1x10-22), but also in BD (p = 1.2x10-6). In risk regions specific to BD (n=19), significantly 260 
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increased regional h2snp was observed in BD, as expected (p = 0.0007), but not in SCZ (p = 0.89). 261 
Risk regions shared by both disorders had significantly higher h2snp in both disorders, as expected 262 
(BD p = 5.3x10-5, SCZ p = 0.006), compared to non-risk regions. However, we observed a 263 
significant increase in BD h2snp in shared risk regions compared to BD risk regions (BD p = 0.003) 264 
but not SCZ h2snp for shared risk regions compared to SCZ risk regions (p = 0.62). Using a less 265 
stringent p-value threshold for defining risk regions (p < 5x10-6), thereby substantially increasing 266 
the number of regions, resulted in similar results. Seven regions contributed to substantially higher 267 
h2snp in SCZ compared to BD but no region showed the inverse pattern. Of these regions, all but 268 
one was in the major histocompatibility region (MHC), the sole novel region was 269 
chr10:104380410-106695047 with regional h2snp= 0.0019 in SCZ and h
2
snp=0.00063 in BD.  270 
 271 
Polygenic dissection of subphenotypes 272 
Subphenotypes were collected for a subset of patients with either BD or SCZ (see Methods). For 273 
SCZ, we had clinical quantitative measurements of manic, depressive, positive and negative 274 
symptoms generated from factor analysis of multiple instruments as described previously(Ruderfer 275 
et al., 2014) but in larger sample sizes (n=6908, 6907, 8259, 8355 respectively). For BD, 24 276 
subphenotypes were collected among nearly 13,000 cases in distinct categories including 277 
comorbidities, clinical information such as rapid cycling and psychotic features as well as 278 
additional disease course data such as age of onset and number of hospitalizations. For each BD 279 
or SCZ patient, we calculated a polygenic risk score (PRS) using all SNPs, from each of the four 280 
main GWAS analyses (BD+SCZ, BD, SCZ and SCZvsBD). We then used regression analysis 281 
including principal components and site to assess the relationship between each subphenotype and 282 
the 4 PRS. Specifically, we tested whether polygenic risk scores of BD+SCZ, BD, SCZ or 283 
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SCZvsBD were correlated with each of these subphenotypes separately within BD and SCZ cases. 284 
When testing if the variance explained by the PRS was different from zero, we applied a 285 
significance cutoff of p < 0.0004 based on Bonferroni correction for 112 tests. In total, we 286 
identified 6 significant results after correction (Figure 2, Table 2). 287 
 288 
A significant positive correlation existed between BD PRS and manic symptoms in SCZ cases as 289 
seen previously(Ruderfer et al., 2014) (p=2x10-5, t=4.26) and BD PRS and psychotic features in 290 
BD patients (p=5.3x10-5, t=4.04). A significant increase in SCZ PRS was seen for BD cases with 291 
versus without psychotic features (p=1.2x10-10, t=6.45) and patients with increased negative 292 
symptoms in SCZ patients (p=3.60x10-6, t=4.64). The BD+SCZ vs controls PRS was significantly 293 
associated with psychotic features in BD (p=7.9x10-13, t=7.17) and negative symptoms in SCZ 294 
(p=1.5x10-5, t=4.33). The next two most significant results which did not survive our conservative 295 
correction were both indicative of a more severe course in BD: increased BD+SCZ PRS with 296 
increased numbers of hospitalizations in BD cases (p=4.2x10-4, t=3.53) and increased SCZ PRS 297 
with earlier onset of BD (p=7.9x10-4, t=-3.36). We assessed the role of BD subtype on the 298 
correlation between SCZ PRS and psychotic features and identified a significant correlation when 299 
restricted to only BD type I cases indicating the result was not likely driven by BD patients with a 300 
schizoaffective subtype (BDI: 3,763 with psychosis, 2,629 without, p=1.55x10-5, Supplementary 301 
Table 4). 302 
 303 
We performed a GWAS for all 8 quantitative subphenotypes and 9 binary subphenotypes with at 304 
least 1,000 cases and calculated heritability and genetic correlation with BD and SCZ. Only two 305 
subphenotypes had significant h2snp estimates using LD-score regression(Bulik-Sullivan et al., 306 
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2015) both in BD: psychotic features in BD (h2snp=0.15, SE=0.06) and suicide attempt (h
2
snp=0.25, 307 
SE=0.1). Only psychotic features demonstrated a significant genetic correlation with SCZ 308 
(rg=0.34, SE=0.13, p=0.009). The significant genetic correlation demonstrates a genome-wide 309 
relationship between common variants contributing to SCZ risk and those contributing to 310 
psychotic features in BD cases. We tested whether the most significantly associated SCZ loci 311 
contributed directly to psychotic features in BD. One hundred of the 105 autosomal genome-wide 312 
significant SCZ SNPs previously published(Schizophrenia Working Group of the Psychiatric 313 
Genomics Consortium, 2014) were in our dataset after QC and 60 were in the same direction of 314 
effect for risk of psychotic features in BD (p=0.028, one-sided binomial-test). 315 
 316 
 317 
Discussion 318 
Here we present a genetic dissection of bipolar disorder and schizophrenia from over 100,000 319 
genotyped subjects. Consistent with earlier results(Cross-Disorder Group of the Psychiatric 320 
Genomics Consortium, 2013), we found extensive genetic sharing between these two disorders, 321 
identifying 114 genome-wide significant loci contributing to both disorders of which 32 are novel. 322 
These findings point to the relevance of neuronal and synaptic biology for the shared genetic 323 
substrate of these disorders. However, despite this degree of sharing, we identified several loci that 324 
significantly differentiated between the two disorders, having opposite directions of effect. We 325 
also found polygenic components that significantly correlated from one disorder to symptoms of 326 
the other. 327 
 328 
Two GWS loci were identified from the case only SCZ versus BD analysis providing opportunities 329 
to inform the underlying biological distinctions between BD and SCZ. The most significant locus 330 
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implicates DARS2 (coding for the mitochondrial Aspartate-tRNA ligase) which is highly expressed 331 
in the brain and significantly regulated by the most significant SNP rs56355601 (peQTL=2.5x10
-11). 332 
Homozygous mutations in DARS2 are responsible for leukoencephalopathy with brainstem and 333 
spinal cord involvement and lactate elevation (LBSL), which was characterized by neurological 334 
symptoms such as psychomotor developmental delay, cerebellar ataxia and delayed mental 335 
development(Yamashita et al., 2013, p. 2). Based on methylation analysis from the prefrontal 336 
cortex of stress models (rats and monkeys) and from peripheral samples (in monkeys and human 337 
newborns), DARS2, among others, has been suggested as a potential molecular marker of early-338 
life stress and vulnerability to psychiatric disorders(Luoni et al., 2016). The second most 339 
significant locus implicates CSE1L, a nuclear transport factor that plays a role in cellular 340 
proliferation as well as in apoptosis(Bera et al., 2001). Intronic SNPs in CSE1L have been 341 
associated with subjective well-being(Okbay et al., 2016) and, nominally to antidepressant 342 
response(Li et al., 2016). More interestingly, CSE1L is a potential target gene of miR-137, one of 343 
the well-known schizophrenia risk loci(Schizophrenia Working Group of the Psychiatric 344 
Genomics Consortium, 2014), which is able to negatively regulate CSE1L by interacting with 345 
complementary sequences in the 3’ UTR of CSE1L(Li et al., 2013). Although falling short of 346 
genome-wide significance, the third most significant locus implicates ARNTL (Aryl Hydrocarbon 347 
Receptor Nuclear Translocator Like), which is a core component of the circadian clock. ARNTL 348 
has been previously hypothesized for relevance in bipolar disorder,(Yang et al., 2008) although 349 
human genetic evidence is currently limited(Byrne et al., 2014).  350 
 351 
The ability to generate transcriptional data on multiple tissues across many individuals using RNA-352 
sequencing has provided detailed information on the role common variants play in regulating 353 
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expression of specific genes in specific tissues. These eQTLs can be integrated with the genetic 354 
association data from GWAS to inform on the relationship between variant association and variant 355 
regulation of expression for each gene. Performing this integration, we identified a third genome-356 
wide significant finding in DCAKD. The gene codes for Dephospho-CoA Kinase Domain 357 
Containing protein, a member of the human postsynaptic density proteome from human 358 
neocortex(Bayés et al., 2011). In the mouse cortical synaptoproteome DCAKD is among the 359 
proteins with the highest changes between juvenile postnatal days and adult stage, suggesting a 360 
putative role in brain development(Gonzalez-Lozano et al., 2016; Moczulska et al., 2014). 361 
Discerning between pleiotropy (variant independently regulates expression and alters risk to 362 
disease) from causality (variant regulates expression which thereby alters risk to disease) through 363 
statistical analysis alone is difficult, this analytical approach is stringent in excluding loci where 364 
colocalised SNP-phenotype and SNP-expression associations may reflect confounding driven by 365 
linkage disequilibrium (LD) (one variant regulates expression and a different variant alters risk but 366 
the variants in the region are in LD). Hence, this approach utilizes currently available data to 367 
prioritize genes, including direction of effect, for functional follow-up. These analyses will become 368 
more powered with increased sample sizes for both phenotype and eQTL data sets. 369 
 370 
Performing pathway analysis based on the full association results shows enrichment of genes 371 
involved in response to potassium ions, including potassium voltage-gated channel subfamily 372 
members and a number of genes regulated by cellular potassium concentration.  This is in line with 373 
previous genetic evidence pointing to a key etiologic role of potassium channels, in particular, in 374 
BD(Judy and Zandi, 2013), which could be explained by their role in multiple neurobiological 375 
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mechanisms involved in the development of psychiatric disorders such as regulation of the 376 
dopaminergic circuits, synaptic plasticity, and myelination(Balaraman et al., 2015). 377 
 378 
We further assessed the contribution of regions of the genome to each disorder through joint 379 
regional association and heritability estimation. These results point to an additional locus that may 380 
contribute differentially to liability to BD and SCZ. The region on chr19 shows overlapping 381 
association peaks that are driven by independent causal variants for each disorder. Both variants 382 
significantly regulate the same gene GATAD2A but in opposite directions. GATAD2A is a 383 
transcriptional repressor, which is targeted by MBD2 and is involved in methylation-dependent 384 
gene silencing. The protein is part of the large NuRD (nucleosome remodeling and deacetylase) 385 
complex, for which also HDAC1/2 are essential components. NurD complex proteins have been 386 
associated with autism(Li et al., 2015). Their members, including GATAD2A, display preferential 387 
expression in fetal brain development(Li et al., 2015) and in recent work has been implicated in 388 
SCZ through open chromatin(Fullard et al., n.d.). Further, p66 (mouse GATAD2A) was recently 389 
shown to participate in memory preservation through long-lasting histone modification in 390 
hippocampal memory-activated neurons(Ding et al., 2017). SNP-heritability appears to be 391 
consistently shared across regions and chromosomes between these two disorders. Regions with 392 
GWS loci often explain higher proportions of heritability as expected. When looking at the effect 393 
on heritability of the presence of a GWS locus in the other disorder, we identified a significant 394 
increase in BD heritability for regions containing a GWS locus for SCZ but no significant increase 395 
in SCZ heritability in regions having a BD one. This result suggests a directionality to the genetic 396 
sharing of these disorders with a larger proportion of BD loci being specific to BD. However, we 397 
cannot exclude that the asymmetry of results may reflect less power of discovery for BD than SCZ. 398 
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The degree to which power and subphenotypes contribute to this result requires further 399 
examination. 400 
 401 
We note that as with nearly all GWAS findings, the calculated population-based effect sizes of the 402 
variants identified here are small and independently explain only a modest fraction to the 403 
heritability of these disorders. The identification of these variants is dependent on the ability to 404 
have highly accurate allele frequency estimates that can only be ascertained from large sample 405 
sizes. As sample sizes get larger the power to identify variants of smaller effect increases meaning 406 
that increasing sample size results in the identification of variants of smaller effect. However, a 407 
small population effect size does not exclude the possibility of a substantially larger effect on 408 
molecular phenotypes nor does it preclude the utility of association regions in understanding 409 
biology or having a clinical impact. Efforts following up GWAS results to date have demonstrated 410 
the value of these findings in pointing to genes that can aid in understanding the underlying biology 411 
of the trait(Claussnitzer et al., 2015; Mohanan et al., 2018; Sekar et al., 2016). Further, there is a 412 
clear relationship between GWAS results of a phenotype and gene targets of drugs that treat that 413 
phenotype pointing to the potential for improved therapeutic understanding(Nelson et al., 2015; 414 
Ruderfer et al., 2016). A major challenge of GWAS is the sheer number of findings and the 415 
substantial time/cost required for functional follow up of these findings in the classical paradigms 416 
used for genes causal for monogenic disorders. In silico bioinformatic analyses (such as SMR used 417 
here) that integrate GWAS results with ‘omics data (transcription, protein, epigenetic, etc.) have 418 
the potential to put a clearer biological focus on GWAS results. Such analyses can become more 419 
complex as more reference omics data sets (with genome-wide genotyping) become available. 420 
Additional analytical efforts will be required to facilitate the transition from GWAS to biology but 421 
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substantial data has shown there is much to be learned from these variants despite their small 422 
effects(Visscher et al., 2017). 423 
 424 
We have now identified multiple genomic signatures that correlate between one disorder and a 425 
clinical symptom in the other disorder, illustrating genetic components underlying particular 426 
symptom dimensions within these disorders. Medical symptoms, including those seen in 427 
psychiatric disorders, can manifest through a multitude of causes. The classic example often used 428 
is headache for which many different paths lead to the same symptom. Psychiatric symptoms also 429 
have many potential causes. For example, symptoms of psychosis can be the result of highly 430 
heritable diseases such as BD and SCZ but also infectious and neurodegenerative diseases, 431 
sleep/sensory deprivation or psychedelic drugs. Demonstrating a shared biological underpinning 432 
to these symptoms suggests they could be treated through modulating the same pathway. As 433 
previously shown, we find a significant positive correlation between the PRS of BD and manic 434 
symptoms in SCZ. We also demonstrate that BD cases with psychotic features carry a significantly 435 
higher SCZ PRS than BD cases without psychotic features and this result is not driven by the 436 
schizoaffective BD subtype. Further, we show that increased PRS is associated with more severe 437 
illness. This is true for BD with psychotic features having increased SCZ PRS, earlier onset BD 438 
having higher SCZ PRS and cases with higher BD+SCZ PRS having a larger number of 439 
hospitalizations. We demonstrated that psychotic features within BD is a heritable trait and GWS 440 
loci for SCZ have a consistent direction of effect in psychotic features in BD, demonstrating the 441 
potential to study psychosis more directly to identify variants contributing to that symptom 442 
dimension.  443 
 444 
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This work illustrates the utility of genetic data, in aggregate, at dissecting symptom heterogeneity 445 
among related disorders and suggests that further work could aid in characterizing patients for 446 
more personalized treatment. Genetic risk scores have demonstrated their ability to inform and 447 
predict pathology(Cleynen et al., 2016) and more recently have been shown to be able to identify 448 
patients with risk equivalent to monogenic variants(Khera et al., 2017). In psychiatry, we lack 449 
objective biological measurements (biomarkers) with which to assess the ability of a genetic 450 
signature to predict or inform. Lacking diagnostic pathology for psychiatric disorders leaves a 451 
genuine opportunity for the genetics to drive diagnosis and treatment to a much larger degree than 452 
in other domains. One potential model assumes that each individual has a quantitative loading of 453 
a series of symptom dimensions (i.e. manic, psychotic, cognitive, etc.) and that these symptoms 454 
can be assessed at the genetic level to characterize a patient’s dysfunction and used to inform 455 
disease course and optimal treatment. Making this a reality will require more detailed information 456 
on disease course and outcomes. For example, if treatment response data existed for these samples 457 
one could ask whether a genetic loading for psychosis was correlated with response to treatment.  458 
Initial work has already shown the potential of this approach using a SCZ PRS to inform lithium 459 
response in BD(Amare et al., 2018). Ultimately, the goal will be to quantify multiple genetic 460 
loadings of each individual’s illness and use those measures to inform treatment based on the 461 
outcomes of previous individuals with similar profiles. 462 
 463 
In conclusion, we present a detailed genetic dissection of BD and SCZ pointing to substantial 464 
shared genetic risk but also demonstrating that specific loci contribute to the phenotypic 465 
differences of these disorders. We show that genetic risk scores can correspond to symptoms 466 
within and across disorders. Finally, we present data that points to these disorders being neither 467 
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independent nor the same but sharing particular symptom dimensions that can be captured from 468 
the genetics and used to characterize patients to ultimately inform diagnosis and treatment. 469 
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Figure Legends 899 
 900 
Figure 1. Associated Genomic Loci Shared and Divergent Between BD and SCZ 901 
a) Odds ratios (OR) from independent data sets of BD (blue) and SCZ (red) for each of the 114 902 
genome-wide significant variants in the BD and SCZ vs controls GWAS. b) Manhattan plot for 903 
SCZ vs BD GWAS. 904 
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 905 
Figure 2. Polygenic Risk Score Dissection of Clinical Symptom Dimensions 906 
Effect size (calculated by dividing regression estimate by standard error) from regression analysis 907 
including ancestry covariates for each subphenotype and PRS for BD (x-axis) and SCZ (y-axis). 908 
Point size represents –log10(p-value) with SCZ (red) and BD (blue). Numbered subphenotypes 909 
are 1) comorbid migraine, 2) panic attacks 3) suicide attempt 4) mixed states 5) rapid cycling 6) 910 
comorbid eating disorder 7) comorbid OCD 8) year of birth 9) suicide ideation 10) panic disorder 911 
11) number of suicide attempts 12) depressive symptoms (SCZ) 13) episodes depressive 14) 912 
episodes total 15) positive symptoms (SCZ) 16) irritable mania 17) age of onset depression 18) 913 
family history 19) episodes mixed mania 20) unipolar mania 21) alcohol substance dependence 914 
22) age of onset mania 23) age at interview 24) number of hospitalizations. All subphenotypes are 915 
in BD except those labeled (SCZ). 916 
 917 
Table Legends 918 
 919 
Table 1. Most Significant Associated Loci from SCZ vs BD GWAS 920 
Association results for the five most significant variants in the SCZ vs BD GWAS with the top 921 
two being genome-wide significant. Each variant includes results from the independent BD vs 922 
controls and SCZ vs controls GWAS and the comparable p-value from a heterogeneity test when 923 
performing a two cohort meta-analysis of SCZ and BD. 924 
 925 
Table 2. Complete Results of Polygenic Risk Score Dissection Analysis 926 
 30 
Polygenic scoring results of all four GWAS phenotypes (BD+SCZ vs controls, BD vs controls, 927 
SCZ vs controls and SCZ vs BD) and 24 subphenotypes from BD and 4 subphenotypes from SCZ, 928 
rows without case/control counts are quantitative measures. Significance and effects are from 929 
regression analysis of subphenotype on PRS including principal components of ancestry and site 930 
as covariates. Effect is the regression estimate divided by the standard error. 931 
 932 
Supplementary Figure Legends 933 
 934 
Figure S1. Related to Figure 1b. Regional Association Plot and Forest Plot for the First 935 
Genome-wide Significant Hit in the SCZ vs BD GWAS.  936 
Figure S2. Related to Figure 1b. Regional Association Plot and Forest Plot for the Second 937 
Genome-wide Significant Hit in the SCZ vs BD GWAS.  938 
 939 
 940 
Figure S3. Related to Summary-data-based Mendelian Randomization. Detailed Association 941 
of DCAKD from SMR. 942 
Results at the DCAKD locus from SMR analysis of SCZ vs BD. Top plot, brown dots represent 943 
the P values for SNPs from SCZ vs BD GWAS, diamonds represent the P values for probes from 944 
the SMR test. Bottom plot, the eQTL P values of SNPs from the Westra study for the 945 
ILMN_1811648 probe tagging DCAKD. The top and bottom plots include all the SNPs available 946 
in the region in the GWAS and eQTL summary data, respectively, rather than only the SNPs 947 
common to both data sets. Highlighted in red is the gene (DCAKD) that passed the SMR and 948 
HEIDI tests. 949 
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 950 
Figure S4. Related to Regional SNP-heritability estimation. Heritability Estimates for BD 951 
and SCZ in Genome-wide Significant Regions of BD and SCZ. 952 
Regional SNP-heritability estimates for SCZ and BD stratified by whether the region contains the 953 
most significant variant in a genome-wide significant locus in BD, SCZ, neither or both. 954 
 955 
 956 
STAR Methods 957 
CONTACT FOR REAGENT AND RESOURCE SHARING  958 
Genotype and phenotype data use is restricted and governed by the Psychiatric Genetics 959 
Consortium. Further information and requests for analytical results or additional information 960 
should be directed to and will be fulfilled by the Lead Contact, Douglas Ruderfer 961 
(douglas.ruderfer@vanderbilt.edu).  962 
 963 
SUBJECT DETAILS 964 
Genotyped Sample Description 965 
SCZ samples are a substantial subset of those analyzed previously(Schizophrenia Working Group 966 
of the Psychiatric Genomics Consortium, 2014). BD samples are the newest collection from 967 
Psychiatric Genomics Consortium Bipolar Disorder Working Group(Stahl et al., 2017).  968 
Below we provide information on the individual samples used here as provided by the original 969 
PGC disorder publications. Additionally, most studies have been described in detail in the citations 970 
provided. The boldfaced first line for each sample is study PI, PubMed ID, country (study name), 971 
and the PGC internal tag or study identifier.  972 
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 973 
European ancestry, case-control design  974 
Schizophrenia 975 
Adolfsson, R | NP | Umeå, Sweden | scz_umeb_eur  976 
Adolfsson, R | NP | Umeå, Sweden | scz_umes_eur  977 
Cases of European ancestry were ascertained from multiple different studies of schizophrenia 978 
(1992-2009). The diagnostic processes were similar between studies, and the final diagnosis is a 979 
best-estimate consensus lifetime diagnosis based on multiple sources of information such as 980 
clinical evaluation by research psychiatrists, different types of semi-structured interviews made by 981 
trained research nurses and research psychiatrists, medical records, course of the disease and data 982 
from multiple informants. Diagnosis was made in accordance with the Diagnostic and Statistical 983 
Manual of Mental Disorders-Version IV (DSM-IV) or International Classification of Diseases, 984 
10th Revision (ICD-10) criteria. Controls were recruited from the Betula study, an ongoing 985 
longitudinal, prospective, population-based study from the same geographic area (North Sweden) 986 
that is studying aging, health, and cognition in adults. All subjects (cases and controls) participated 987 
after giving written informed consent and the regional Ethical Review Board at the University of 988 
Umeå approved all original studies and participation in the PGC. GWAS genotyping was 989 
performed at Broad Institute.  990 
Andreassen, O | 19571808 | Norway (TOP) | scz_top8_eur  991 
In the TOP study (Tematisk omrade psykoser), cases of European ancestry, born in Norway, were 992 
recruited from psychiatric hospitals in the Oslo region. Patients were diagnosed according to SCID 993 
and further ascertainment details have been reported. Healthy control subjects were randomly 994 
selected from statistical records of persons from the same catchment area as the patient groups. 995 
 33 
All participants provided written informed consent and the human subjects protocol was approved 996 
by the Norwegian Scientific-Ethical Committee and the Norwegian Data Protection Agency.  997 
Blackwood, D | 19571811 | Edinburgh, UK | scz_edin_eur  998 
Cases and controls were recruited from the southeast of Scotland, and ascertainment has been 999 
previously described as part of the International Schizophrenia Consortium studies. All 1000 
participating subjects gave written, informed consent and the human subjects protocol was 1001 
approved by the Scotland A Research Ethics Committee. DNA samples were genotyped at the 1002 
Broad Institute.  1003 
Børglum, A | 19571808 | Denmark | scz_aarh_eur  1004 
DNA samples for all subjects were collected from blood spots systematically collected by the 1005 
Danish Newborn Screening Biobank), with case/control status established using the Danish 1006 
Psychiatric Central Register. Cases were diagnosed clinically according to ICD-10 criteria. 1007 
Controls were selected to match the cases by birth cohort. The Danish Data Protection Agency and 1008 
the ethics committees in Denmark approved the human subjects protocol.  1009 
Bramon | 23871474 | Seven countries (PEIC, WTCCC2) | scz_pewb_eur  1010 
Bramon | 23871474 | Spain (PEIC, WTCCC2) | scz_pewb_eur  1011 
The Psychosis Endophenotypes International Consortium (PEIC) was part of WTCCC2. Samples 1012 
were collected through seven centers in Europe and Australia (the Institute of Psychiatry, King’s 1013 
College London, London; GROUP (consisting of the University of Amsterdam, Amsterdam; the 1014 
University of Groningen, Groningen; Maastricht University Medical Centre, Maastricht; and the 1015 
University of Utrecht, Utrecht); the University of Western Australia, Perth; the Universidad de 1016 
Cantabria, Santander; the University of Edinburgh, Edinburgh; Heidelberg University, Heidelberg 1017 
and Ludwig-Maximilians-Universität München, Munich). To allow for a DSM-IV diagnosis to be 1018 
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ascertained or ruled out, all participants (including controls and unaffected family members) 1019 
underwent a structured clinical interview with the Schedule for Affective Disorders and 1020 
Schizophrenia (SADS), the Structured Clinical Interview for DSM Disorders (SCID), or the 1021 
Schedules for Clinical Assessment in Neuropsychiatry (SCAN). We included cases with 1022 
schizophrenia and schizoaffective disorder. Participants in all groups were excluded if they had a 1023 
history of neurological disease or head injury resulting in loss of consciousness.  1024 
Buxbaum, J | 20489179 | New York, US & Israel | scz_msaf_eur  1025 
Samples contributed by Mount Sinai were derived from three cohorts. In all cohorts, ethical 1026 
approval was obtained from all participating sites, and all subjects provided informed consent. 1027 
Two of the cohorts were in a prior paper on copy number variation. One of the cohorts was from 1028 
the Mount Sinai brain bank, where DNA was extracted from postmortem samples, and another 1029 
comprised of patients ascertained in Israel. The third cohort included subjects more recently 1030 
recruited through the Mount Sinai Conte Center.  1031 
Corvin, A | 19571811 | Ireland | scz_dubl_eur  1032 
The case sample was collected primarily in the Dublin area and the ascertainment procedure has 1033 
been previously described. The controls were recruited, from the same region through the Irish 1034 
Blood Transfusion Services. All participants gave written, informed consent and the collections 1035 
were approved through the Federated Dublin Hospitals and Irish Blood Transfusion Services 1036 
Research Ethics Committees, respectively. DNA samples were genotyped at the Broad Institute.  1037 
Corvin, A; Riley, B | 22883433 | Ireland (WTCCC2) | scz_irwt_eur  1038 
The case sample was recruited from the Republic of Ireland and Northern Ireland. All cases had 1039 
four Irish grandparents and ascertainment details have been reported elsewhere. Ethics approval 1040 
was obtained from all participating hospitals and centers. Controls were blood donors from the 1041 
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Irish Blood Transfusion Service, whose Ethics Committee approved the human subjects protocol. 1042 
All participants gave written informed consent. Samples were genotyped at Affymetrix (Santa 1043 
Clara, California, US) laboratory as part of the WTCCC2 genotyping pipeline.  1044 
Ehrenreich, H | 20819981 | Germany (GRAS) | scz_gras  1045 
The Gottingen Research Association for Schizophrenia (GRAS) collection included cases 1046 
recruited across 23 German hospitals. Controls were unscreened blood donors recruited at the 1047 
Georg-August-University according to national blood donation guidelines. Cases completed a 1048 
structured clinical interview and were diagnosed with DSM-IV schizophrenia or schizoaffective 1049 
disorder. The study was approved by the Georg-August-University ethics committee and local 1050 
internal review boards of the participating centers. All participants gave written informed consent.  1051 
Esko, T | 15133739 | Estonia (EGCUT) | scz_egcu_eur  1052 
The Estonian cohort comes from the population-based biobank of the Estonian Genome Project of 1053 
University of Tartu (EGCUT). The project was conducted according to the Estonian Gene 1054 
Research Act and all participants provided informed consent (www.biobank.ee). In total, 52,000 1055 
individuals aged 18 years or older participated in this cohort (33% men, 67% women). The 1056 
population distributions of the cohort reflect those of the Estonian population (83% Estonians, 1057 
14% Russians and 3% other). General practitioners (GP) and physicians in the hospitals randomly 1058 
recruited the participants. A Computer-Assisted Personal interview was conducted over 1-2 ours 1059 
at doctors’ offices. Data on demographics, genealogy, educational and occupational history, 1060 
lifestyle and anthropometric and physiological data were assessed. Schizophrenia was diagnosed 1061 
prior to the recruitment by a psychiatrist according to ICD-10 criteria and identified from the 1062 
Estonian Biobank phenotype database. Controls were drawn from a larger pool of genotyped 1063 
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biobank samples by matching on gender, age and genetic ancestry. All the controls were 1064 
population-based and have not been sampled for any specific disease.  1065 
Esko, T; Li, Q; Dominici E | 15133739, 24166486 | J&J and Roche cases, EGCUT controls | 1066 
scz_jr3a_eur  1067 
Esko, T; Li, Q; Domenici E | 15133739, 24166486 | J&J and Roche cases, EGCUT controls | 1068 
scz_jr3b_eur  1069 
Esko, T; Li, Q; Domenici E | 15133739, 24166486 | J&J and Roche cases, EGCUT controls | 1070 
scz_jri6_eur  1071 
Esko, T; Li, Q; Dominici E | 15133739, 24166486 | J&J and Roche cases cases, EGCUT 1072 
controls | scz_jrsa_eur  1073 
Cases were collected by Johnson and Johnson (J&J) and Roche as part of clinical collaborations 1074 
with hospitals and outpatient centers. Cases were diagnosed according to DSMIV criteria, with 1075 
medical record review by a trained psychiatrist. There were reliability trials across centers for the 1076 
J&J studies. The J& J cases were mostly collected in Eastern Europe, with most coming from 1077 
Estonian and Russia (>100); intermediate numbers from Austria, the Czech Republic, Latvia, 1078 
Lithuania, and Spain (50-100); and smaller collections from Bulgaria, Hungary, and Poland (<50). 1079 
The Roche cases were assessed with a structured psychiatric assessment by trained interviewers. 1080 
Most of the Eastern European controls were from the Estonian Biobank project (EGCUT) and 1081 
were ancestrally matched with cases from the J&J sample.  1082 
Gejman, P | 19571809 | US, Australia (MGS) | scz_mgs2_eur  1083 
European ancestry case samples were collected by the Molecular Genetics of Schizophrenia 1084 
(MGS) collaboration across multiple sites in the USA and Australia as described in detail 1085 
elsewhere. Cases gave written informed consent, and IRBs at each collecting site approved the 1086 
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human subjects protocol. A survey company (Knowledge Networks, under MGS guidance) 1087 
collected the European ancestry control sample and ascertainment is described in detail elsewhere. 1088 
DNA samples were genotyped at the Broad Institute.  1089 
Gurling, H | 19571811 | London, UK | scz_uclo_eur  1090 
All cases and controls were collected by University College London and had both parents from 1091 
England, Scotland or Wales. All participants gave written informed consent and the U.K. National 1092 
Health Service multicenter and local research ethics committee approved the human subjects 1093 
protocol. Further details on ascertainment are available elsewhere. The samples were genotyped 1094 
at the Broad Institute.  1095 
Jönsson, E | 19571808 | Sweden (Hubin) | scz_ersw_eur  1096 
Cases were recruited from northwestern Stockholm County and ascertainment has been described 1097 
previously. Cases gave informed consent and the human subjects protocol was approved by the 1098 
ethical committees of the Karolinska Hospital and the Stockholm Regional Ethical Committee. 1099 
Controls were recruited either among subjects previously participating in biological research at the 1100 
Karolinska Institute or drawn from a representative register of the population of Stockholm 1101 
County. All participants provided informed consent.  1102 
Kirov, G | Not published | Bulgaria | scz_buls_eur  1103 
All cases were recruited from Bulgaria and had a history of hospitalization for treatment of 1104 
schizophrenia. Controls were recruited from the two largest cities in Bulgaria as previously 1105 
described. All participants gave written informed consent and the study was approved by local 1106 
ethics committees at the participating centers.  1107 
Knight, J; Collier DA; Nisenbaum L| Not published | Canada (Toronto) -US(Lilly)-US 1108 
(MIGen)| scz_lktu_eur  1109 
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Toronto cases were recruited by referral and advertisement. Diagnoses were made according to 1110 
DSM-III or DSM-IV criteria following interview and medical record review. US cases were 1111 
recruited from schizophrenia clinical trials in a range of settings as part of a trial with Eli Lilly. 1112 
Diagnoses were made according to DSM-III or DSM-IV criteria following interview by 1113 
psychiatrist and medical record review. No controls were sampled as part of the study, and 1114 
ancestrally-matched controls were chosen from the Myocardial Infarction Genetics Consortium 1115 
(MIGen, dbGaP ID phs000294.v1.p1) that was genotyped with the same SNP array.  1116 
Lencz, T; Darvasi A | 23325106 | Israel | scz_ajsz_eur  1117 
Cases and controls were sampled from an Ashkenazi Jewish repository (Hebrew University 1118 
Genetic Resource, http://hugr.huji.ac.il). Patients were recruited from hospitalized inpatients at 7 1119 
medical centers in Israel and were diagnosed with DSM-IV schizophrenia or schizoaffective 1120 
disorder. Controls were sampled through the Israeli Blood Bank and did not report any chronic 1121 
disease or regularly prescribed medication at the time of assessment. Full ascertainment details 1122 
have previously been reported. Local ethics committees and the National Genetic Committee of 1123 
the Israeli Ministry of Health approved the studies and all participants gave informed, written 1124 
consent.  1125 
Levinson, D | 22885689 | Six countries, WTCCC controls | scz_lacw_eur  1126 
Cases collected as part of a larger pedigree-based study were partitioned into two subsamples. 1127 
Cases with two genotyped parents were analyzed as trios (see PI Levinson, ms.scz_lemu_eur in 1128 
the Trio section below). Unrelated cases who could not be used as part of a trio were included as 1129 
a separate case-control analysis, using independent controls, matched by ancestry and genotyping 1130 
array, from the Wellcome Trust Case Control Consortium. Cases were identified from different 1131 
clinical settings (e.g. inpatients, outpatients and community facilities) in six countries (Australia, 1132 
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France, Germany, Ireland, UK, and the US). Diagnoses were established using semi-structured 1133 
interviews, psychiatric records and informant reports. Case subjects were diagnosed with 1134 
schizophrenia or schizoaffective disorder according to DSM-III-R criteria. All protocols were 1135 
approved by loci IRBs, and all cases provided written informed consent.  1136 
Malhotra, A | 17522711 | New York, US | scz_zhh1_eur  1137 
The case and control subjects were recruited in the New York metropolitan area and ascertainment 1138 
methods have been described previously. All participants gave written, informed consent and the 1139 
IRB of the North Shore-Long Island Jewish Health System approved the human subjects protocols. 1140 
DNA was genotyped at Zucker Hillside.  1141 
Mowry, B | 21034186 | Australia | scz_asrb_eur  1142 
These subjects were part of the Australian Schizophrenia Research Bank. The case sample was 1143 
recruited in four Australian States (New South Wales, Queensland, Western Australia and 1144 
Victoria) through hospital inpatient units, community mental health services, outpatient clinics and 1145 
rehabilitation services, non-government mental illness support organizations, and, in the initial 1146 
stages, through a large-scale, national, multi-media advertising campaign. This sample is 1147 
comprised of 509 cases from larger metropolitan centers of Brisbane, Newcastle, Sydney, 1148 
Melbourne, and Perth. Cases gave written informed consent, and the human subjects protocol was 1149 
initially approved by the Hunter New England Area Health Research Committee and subsequently 1150 
approved by relevant Institutional Ethics Committees in Brisbane, Sydney, Melbourne and Perth. 1151 
Healthy controls were recruited through multi-media advertisements, and other sources. Controls 1152 
were from the metropolitan centers of Brisbane, Newcastle, Sydney, Melbourne, and Perth. 1153 
Controls gave written informed consent, and the human subjects protocol was approved by the 1154 
Hunter New England Area Health Research Committee and Institutional Ethics Committees in 1155 
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Brisbane, Sydney, Melbourne and Perth. The samples were genotyped in two stages at the Hunter 1156 
Medical Research Institute, University of Newcastle, Newcastle, Australia.  1157 
O'Donovan, M: Owen, M | 19571811 | Cardiff, UK | scz_caws_eur  1158 
The case sample included European ancestry schizophrenia cases recruited in the British Isles and 1159 
described previously. All cases gave written informed consent to. The study was approved by the 1160 
Multicentre Research Ethics Committee in Wales and Local Research Ethics Committees from all 1161 
participating sites. The control sample used the Wellcome Trust CaseControl Consortium 1162 
(WTCCC) sample described elsewhere, but included similar numbers of individuals from the 1958 1163 
British Birth Cohort and a panel of consenting blood donors (UK Blood Service). Samples were 1164 
genotyped at Affymetrix service lab (San Francisco, USA).  1165 
O'Donovan, M: Owen, M: Walters, J | 22614287 | UK (CLOZUK) | scz_clm2_eur  1166 
O'Donovan, M: Owen, M: Walters, J | 22614287 | UK (CLOZUK) | scz_clo3_eur  1167 
CLOZUK cases were taking the antipsychotic clozapine and had received a clinical diagnosis of 1168 
treatment-resistant schizophrenia. Patients taking clozapine provide blood samples to allow 1169 
detection of adverse drug-effects. Through collaboration with Novartis (the manufacturer of a 1170 
proprietary form of clozapine, Clozaril), we acquired blood from people with treatment-resistant 1171 
schizophrenia according to the clozapine registration forms completed by treating psychiatrists as 1172 
previously reported. The samples were genotyped at the Broad Institute. The UK Multicentre 1173 
Research Ethics Committee (MREC) approved the study. The controls were drawn from the 1174 
WTCCC2 control samples (~3,000 from the 1958 British Birth Cohort and ~3,000 samples from 1175 
the UK Blood Service Control Group). An additional 900 controls, held by Cardiff University, 1176 
were recruited from the UK National Blood Transfusion Service. They were not specifically 1177 
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screened for psychiatric illness. All control samples were from participants who provided informed 1178 
consent.  1179 
Ophoff, R | 19571808 | Netherlands | scz_ucla_eur  1180 
The case sample consisted of inpatients and outpatients recruited through psychiatric hospitals and 1181 
institutions throughout the Netherlands. Cases with DSM-IV schizophrenia were included in the 1182 
analysis. Further details on ascertainment are provided elsewhere. Controls came from the 1183 
University Medical Centre Utrecht and were volunteers with no psychiatric history. Ethical 1184 
approval was provided by local ethics committees and all participants gave written informed 1185 
consent.  1186 
Palotie, A | 19571808 | Finland | scz_fi3m_eur  1187 
Palotie, A | Not published | Finnish | scz_fii6_eur  1188 
Finnish cases were drawn from a nationwide collection of families with schizophrenia spectrum 1189 
disorders. The control sample was derived from the Finnish Health 2000 survey. All participants 1190 
provided written informed consent and approval was obtained from the ethics committees at each 1191 
location.  1192 
Pato, C | 19571811 | Portugal | scz_port_eur  1193 
Cases and controls lived in Portugal, the Azorean and Madeiran islands, or were the direct (firstor 1194 
second-generation) Portugese immigrant population in the US, as previously described. Controls 1195 
were not biologically related to cases. All participants gave written informed consent and the IRB 1196 
of SUNY Upstate Medical University approved the protocol. The samples were genotyped at the 1197 
Broad Institute.  1198 
Petryshen, T | 24424392| Boston, US (CIDAR) | scz_cims_eur  1199 
 42 
Cases were recruited from inpatient and outpatient settings in the Boston area by clinician referral, 1200 
through review of medical records, or through advertisements in local media. Cases were 1201 
diagnosed with DSM-IV schizophrenia through a structured clinical interview (SCID) by trained 1202 
interviewers with review of medical records and a best estimate diagnostic procedure including 1203 
reliability trials across interviewers. A psychiatrist or a PhD-level mental health professional made 1204 
the final diagnostic determination. Controls were ascertained through local advertisements from 1205 
the same geographical area. Ethical approval was provided by local ethics committees and all 1206 
participants gave written informed consent.  1207 
Rietschel/Rujescu/Nöthen | 19571808 | Bonn/Mannheim, Germany | scz_boco_eur  1208 
These German samples were collected by separate groups within the MooDS Consortium in 1209 
Mannheim, Bonn, Munich and Jena. For the PGC analyses, the samples were combined by chip 1210 
and ancestry. In Bonn/Mannheim, cases were ascertained as previously described. Controls were 1211 
drawn from three population-based epidemiological studies (PopGen), the Cooperative Health 1212 
Research in the Region of Augsburg (KORA) study, and the Heinz Nixdorf Recall (HNR) study. 1213 
All participants gave written informed consent and the local ethics committees approved the 1214 
human subjects protocols. Additional controls were randomly selected from a Munich-based 1215 
community sample and screened for the presence of anxiety and affective disorders using the 1216 
Composite International Diagnostic Screener. Only individuals negative for the above mentioned 1217 
disorders were included in the sample.  1218 
Rujescu, D | 19571808 | Munich, Germany | scz_munc_eur  1219 
For the Munich sample, cases were ascertained from the Munich area of Germany, as described 1220 
previously. The controls were unrelated volunteers randomly selected from the general population 1221 
of Munich. All were screened to exclude a history of psychosis/central neurological disease either 1222 
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personally or in a first-degree relative. All participants gave written informed consent and the local 1223 
ethics committees approved the human subjects protocols.  1224 
St Clair, D | 19571811 | Aberdeen, UK | scz_aber_eur  1225 
Ascertainment and inclusion/exclusion criteria for cases and controls have been previously 1226 
described. All participating subjects were born in the UK (95% Scotland) and gave written 1227 
informed consent. Both local and multiregional academic ethical committee approved the human 1228 
subjects protocol. The samples were genotyped at the Broad Institute.  1229 
Sullivan, PF | 18347602 | US (CATIE) | scz_cati_eur  1230 
Cases were collected as part of the Clinical Antipsychotics Trials of Intervention Effectiveness 1231 
(CATIE) project and ascertainment was previously described. Participants were recruited from 1232 
multiple sites in the USA with informed written consent and approval from the IRBs at each 1233 
CATIE site and the University of North Carolina (Chapel Hill). The control subjects were collected 1234 
by MGS (described above) and gave online informed consent and were fully anonymized. There 1235 
was no overlap with controls included in the MGS collaboration sample.  1236 
Sullivan, PF; Sklar P; Hultman C | 23974872 | Sweden | scz_swe1_eur  1237 
Sullivan, PF; Sklar P; Hultman C | 23974872 | Sweden | scz_s234_eur  1238 
Sullivan, PF; Sklar P; Hultman C | 23974872 | Sweden | scz_swe5_eur  1239 
Sullivan, PF; Sklar P; Hultman C | 23974872 | Sweden | scz_swe6_eur  1240 
Samples from the Swedish Schizophrenia Study were collected in a multi-year project and 1241 
genotypes in six batches (sw1-6). All procedures were approved by ethical committees at the 1242 
Karolinska Institutet and the University of North Carolina, and all subjects provided written 1243 
informed consent (or legal guardian consent and subject assent). All samples were genotyped at 1244 
the Broad Institute. Cases with schizophrenia were identified via the Swedish Hospital Discharge 1245 
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Register which captures all public and private inpatient hospitalizations. The register is complete 1246 
from 1987 and is augmented by psychiatric data from 1973-1986. The register contains 1247 
International Classification of Disease discharge diagnoses made by attending physicians for each 1248 
hospitalization. Case inclusion criteria included ≥2 hospitalizations with a discharge diagnosis of 1249 
schizophrenia, both parents born in Scandinavia and age ≥18 years. Case exclusion criteria 1250 
included hospital register diagnosis of any medical or psychiatric disorder mitigating a confident 1251 
diagnosis of schizophrenia as determined by expert review. The validity of this case definition of 1252 
schizophrenia was strongly supported by clinical, epidemiological, genetic epidemiological and 1253 
genetic evidence. Controls were selected at random from Swedish population registers, with the 1254 
goal of obtaining an appropriate control group and avoiding ‘super-normal’ controls. Control 1255 
inclusion criteria included never being hospitalized for schizophrenia or bipolar disorder (given 1256 
evidence of genetic overlap with schizophrenia), both parents born in Scandinavia and age of ≥18 1257 
years.  1258 
Walters, J | 21850710 | Cardiff, UK (CogUK) | scz_cou3_eur  1259 
Cases were recruited from community mental health teams in Wales and England on the basis of 1260 
a clinical diagnosis of schizophrenia or schizoaffective disorder (depressed sub-type) as described 1261 
previously. 35 Diagnosis was confirmed following a SCAN interview and review of case notes 1262 
followed by consensus diagnosis according to DSM-IV criteria. The samples were genotyped at 1263 
the Broad Institute. The UK Multicentre Research Ethics Committee (MREC) approved the study 1264 
and all participants provided valid informed consent.  1265 
Weinberger, D | 11381111 | NIMH CBDB | scz_lie2_eur  1266 
Weinberger, D | 11381111 | NIMH CBDB | scz_lie5_eur  1267 
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Subjects were recruited from the Clinical Brain Disorders Branch of the NIMH ‘Sibling Study’ as 1268 
previously described. In brief, cases and controls gave informed consent and only participants of 1269 
European ancestry were included in the current analysis. Cases completed a structured clinical 1270 
interview and were diagnosed with schizophrenia-spectrum disorders. Samples were genotyped at 1271 
the NIMH.  1272 
Wendland/Schubert | Pfizer | Not Published | Multiple countries | scz_pfla_eur  1273 
Pfizer contributed anonymized individual genotypes for cases from seven multi-center 1274 
randomized, double-blind efficacy and safety clinical trials (A1281063, A1281134, A1281148, 1275 
A245-102, NRA7500001, NRA7500002, NRA7500003, and NRA7500004) as well as a set of 1276 
purchased samples (NRA9000099). Trial samples were collected for antipsychotic medications 1277 
across outpatient and inpatient treatment settings. All participating cases had a diagnosis of 1278 
schizophrenia and were assessed using a structural clinical interview by trained interviewers, with 1279 
systematic procedures to quality-control diagnostic accuracy and reliability trials across 1280 
participating sites in the United States and internationally. Purchased blood samples were obtained 1281 
from PrecisionMed International by Pharmacia and Upjohn Corporation, and were collected from 1282 
diagnosed subjects with schizophrenia and schizoaffective disorder. All studies were reviewed by 1283 
both central and local institutional review boards, depending on the study site, before recruitment 1284 
of subjects started. Protocol amendments were approved while the study was in progress and 1285 
before the data were unblinded. The studies were conducted in conformity with the U.S. Food and 1286 
Drug Administration Code of Federal Regulations (21CFR, Part 50) and the Declaration of 1287 
Helsinki and its amendments, and were consistent with Good Clinical Practice and the applicable 1288 
regulatory requirements. Participants provided written informed consent before enrollment. An 1289 
optional blood sample was collected from clinical trial subjects for pharmacogenetic analysis to 1290 
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investigate potential associations between genetic variant drug response and general characteristics 1291 
of schizophrenia and related disorders. Sample collection was not required for participation in the 1292 
original clinical trials. The controls (A9011027) were recruited in a multi-site, cross-sectional, 1293 
non-treatment prospective trial to collect data, including DNA, from cognitive normal and free of 1294 
psychiatric diseases elderly subjects in the US. Subjects were specifically recruited to match the 1295 
gender, age, and ethnicity information from the LEADe and UCSD MCI studies. The study 1296 
described here is within the scope of patient consent.  1297 
Werge, T | 19571808 | Denmark | scz_denm_eur  1298 
Cases were ascertained through psychiatric departments and twin pair studies, and were of Danish 1299 
parentage for at least the prior three generations. The controls were collected at the University of 1300 
Aarhus, and included 500 medical students, all of Danish parentage for at least three generations. 1301 
All subjects gave written informed consent and the Danish Data Protection Agency and the ethics 1302 
committees of Denmark approved the human subjects protocol. 1303 
 1304 
Bipolar Disorder 1305 
Adolfsson, R | Not published | Umeå, Sweden | bip_ume4_eur 1306 
Clinical characterization of the patients included the Mini-International Neuropsychiatric 1307 
Interview (MINI), the Diagnostic Interview for Genetic Studies (DIGS), the Family Interview for 1308 
Genetic Studies (FIGS) and the Schedules for Clinical Assessment in Neuropsychiatry (SCAN). 1309 
The final diagnoses were made according to the DSM-IV-TR and determined by consensus of 2 1310 
research psychiatrists. The unrelated Swedish control individuals, consisting of a large population-1311 
based sample representative of the general population of the region, were randomly selected from 1312 
the ‘Betula study’. 1313 
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Alda, M; Smoller, J | Not published | Nova Scotia, Canada; I2B2 controls | bip_hal2_eur 1314 
The case samples were recruited from patients longitudinally followed at specialty mood disorders 1315 
clinics in Halifax and Ottawa (Canada). Cases were interviewed in a blind fashion with the 1316 
Schedule of Affective Disorders and Schizophrenia-Lifetime version (SADS-L) and consensus 1317 
diagnoses were made according to DSM-IV and Research Diagnostic Criteria (RDC). Protocols 1318 
and procedures were approved by the local Ethics Committees and written informed consent was 1319 
obtained from all patients before participation in the study. Control subjects were drawn from the 1320 
I2B2 (Informatics for Integrating Biology and the Bedside) project. The study consists of de-1321 
identified healthy individuals recruited from a healthcare system in the Boston, MA, US area. The 1322 
de-identification process meant that the Massachusetts General Hospital Institutional Review 1323 
Board elected to waive the requirement of seeking informed consent as detailed by US Code of 1324 
Federal Regulations, Title 45, Part 46, Section 116 (46.116). 1325 
Andreassen, OA | PMID:21926972 [PGC1], PMID:20451256 | Norway (TOP) | bip_top7_eur 1326 
In the TOP study (Tematisk omrade psykoser), cases of European ancestry, born in Norway, were 1327 
recruited from psychiatric hospitals in the Oslo region. Patients were diagnosed according to the 1328 
SCID and further ascertainment details have been reported. Healthy control subjects were 1329 
randomly selected from statistical records of persons from the same catchment area as the patient 1330 
groups. The control subjects were screened by interview and with the Primary Care Evaluation of 1331 
Mental Disorders (PRIME-MD). None of the control subjects had a history of moderate/severe 1332 
head injury, neurological disorder, mental retardation or an age outside the age range of 18-60 1333 
years. Healthy subjects were excluded if they or any of their close relatives had a lifetime history 1334 
of a severe psychiatric disorder. All participants provided written informed consent and the human 1335 
subjects protocol was approved by the Norwegian Scientific-Ethical Committee and the 1336 
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Norwegian Data Protection Agency. 1337 
Andreassen, OA | Not published | Norway (TOP) | bip_top8_eur 1338 
The TOP8 bipolar disorder cases and controls were ascertained in the same way as the 1339 
bip_top7_eur (TOP7) samples described above, and recruited from hospitals across Norway. 1340 
Biernacka, JM; Frye, MA | 27769005 | Mayo Clinic, USA | bip_may1_eur 1341 
Bipolar cases were drawn from the Mayo Clinic Bipolar Biobank. Enrolment sites included Mayo 1342 
Clinic, Rochester, Minnesota; Lindner Center of HOPE/University of Cincinnati College of 1343 
Medicine, Cincinnati, Ohio; and the University of Minnesota, Minneapolis, Minnesota. Enrolment 1344 
at each site was approved by the local Institutional Review Board approval, and all participants 1345 
consented to use of their data for future genetic studies. Participants were identified through routine 1346 
clinical appointments, from in-patients admitted in mood disorder units, and recruitment 1347 
advertising. Participants were required to be between 18 and 80 years old and be able to speak 1348 
English, provide informed consent, and have DSM-IV-TR diagnostic confirmation of type 1 or 2 1349 
bipolar disorder or schizoaffective bipolar disorder as determined using the SCID.  Controls were 1350 
selected from the Mayo Clinic Biobank. Potential controls with ICD9 codes for bipolar disorder, 1351 
schizophrenia or related diagnoses in their electronic medical record were excluded. 1352 
Blackwood, D | 18711365 [PGC1] | Edinburgh, UK | bip_edi1_eur 1353 
This sample comprised Caucasian individuals contacted through the inpatient and outpatient 1354 
services of hospitals in South East Scotland. A BD-I diagnosis was based on an interview with the 1355 
patient using the SADS-L supplemented by case note review and frequently by information from 1356 
medical staff, relatives and caregivers. Final diagnoses, based on DSM-IV criteria were reached 1357 
by consensus between two trained psychiatrists. Ethnically-matched controls from the same region 1358 
were recruited through the South of Scotland Blood Transfusion Service. Controls were not 1359 
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directly screened to exclude those with a personal or family history of psychiatric illness. The 1360 
study was approved by the Multi-Centre Research Ethics Committee for Scotland and patients 1361 
gave written informed consent for the collection of DNA samples for use in genetic studies. 1362 
Breen, G; Vincent, JB | 24387768; 19416921; 21926972 [PGC1] |London, UK; Toronto, 1363 
Canada [BACC] | bip_bac1_eur 1364 
The total case/control cohort (N=1922) includes 871 subjects from Toronto, Canada (N=431 cases 1365 
(160 male; 271 female); N=440 controls (176 male; 264 female)), 1051 subjects from London, UK 1366 
(N=538 cases (180 male; 358 female); N=513 controls (192 male; 321 female)). A summary of 1367 
mean and median age at interview, age of onset (AOO), diagnostic subtypes (BD 1 versus BD 2), 1368 
presence of psychotic symptoms, suicide attempt and family history of psychiatric disorders has 1369 
been provided previously for both the Toronto and London cohorts. From the Toronto site (Centre 1370 
for Addiction & Mental Health (CAMH)), BD individuals and unrelated healthy controls matched 1371 
for age, gender and ethnicity were recruited. Inclusion criteria for patients: a) diagnosed with 1372 
DSMIV/ICD 10 BD 1 or 2; b) 18 years old or over; c) Caucasian, of Northern and Western 1373 
European origin, and three out of four grandparents also N.W. European Caucasian. Exclusion 1374 
criteria include: a) Use of intravenous drugs; b) Evidence of intellectual disability; c) Related to 1375 
an individual already in the study; d) Manias that only ever occurred in relation to or resulting 1376 
from alcohol or substance abuse/dependence, or medical illness; e) Manias resulting from non-1377 
psychotropic substance usage. The SCAN interview (Schedule for Clinical Assessments in 1378 
Neuropsychiatry) was used for subject assessment. Using the SCAN interview along with case 1379 
note review, each case was assigned DSM-IV and ICD 10 diagnoses by two independent 1380 
diagnosticians, according to lifetime consensus best-estimate diagnosis. Lifetime occurrence of 1381 
psychiatric symptoms was also recorded using the OPCRIT checklist, modified for use with mood 1382 
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disorders. Similar methods and criteria were also used to collect a sample of 538 BD cases and 1383 
513 controls for the London cohort (King’s College London; KCL). Both studies were approved 1384 
by respective institutional research ethics committees (the CAMH Research Ethics Board (REB) 1385 
in Toronto, and the College Research Ethics Committee (CREC) at KCL), and informed written 1386 
consent was obtained from all participants. GWAS results have previously been published for the 1387 
entire KCL/CAMH cohort. 1388 
Corvin, A | 18711365 [PGC1] | Ireland | bip_dub1_eur 1389 
Samples were collected as part of a larger study of the genetics of psychotic disorders in the 1390 
Republic of Ireland, under protocols approved by the relevant IRBs and with written informed 1391 
consent that permitted repository use. Cases were recruited from Hospitals and Community 1392 
psychiatric facilities in Ireland by a psychiatrist or psychiatric nurse trained to use the SCID. 1393 
Diagnosis was based on the structured interview supplemented by case note review and collateral 1394 
history where available. All diagnoses were reviewed by an independent reviewer. Controls were 1395 
ascertained with informed consent from the Irish GeneBank and represented blood donors who 1396 
met the same ethnicity criteria as cases. Controls were not specifically screened for psychiatric 1397 
illness. 1398 
Rietschel, M; Nöthen, MM, Cichon, S | 21926972 [PGC1] | BOMA-Germany I | 1399 
bip_bonn_eur 1400 
Cases for the BOMA-Bipolar Study were ascertained from consecutive admissions to the inpatient 1401 
units of the Department of Psychiatry and Psychotherapy at the University of Bonn and at the 1402 
Central Institute for Mental Health in Mannheim, University of Heidelberg, Germany. DSM-IV 1403 
lifetime diagnoses of bipolar I disorder were assigned using a consensus best-estimate procedure, 1404 
based on all available information, including a structured interview with the SCID and SADS-L, 1405 
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medical records, and the family history method. In addition, the OPCRIT checklist was used for 1406 
the detailed polydiagnostic documentation of symptoms. Controls were ascertained from three 1407 
population-based studies in Germany (PopGen, KORA, and Heinz-Nixdorf-Recall Study). The 1408 
control subjects were not screened for mental illness. Study protocols were reviewed and approved 1409 
in advance by Institutional Review Boards of the participating institutions. All subjects provided 1410 
written informed consent. 1411 
Rietschel, M; Nöthen, MM; Schulze, TG; Reif, A; Forstner, AJ | 24618891 | BOMA-Germany 1412 
II | bip_bmg2_eur 1413 
Cases were recruited from consecutive admissions to psychiatric in-patient units at the University 1414 
Hospital Würzburg. All cases received a lifetime diagnosis of BD according to the DSM-IV criteria 1415 
using a consensus best-estimate procedure based on all available information, including semi-1416 
structured diagnostic interviews using the Association for Methodology and Documentation in 1417 
Psychiatry, medical records and the family history method. In addition, the OPCRIT system was 1418 
used for the detailed polydiagnostic documentation of symptoms. 1419 
Control subjects were ascertained from the population-based Heinz Nixdorf Recall (HNR) Study. 1420 
The controls were not screened for a history of mental illness. Study protocols were reviewed and 1421 
approved in advance by Institutional Review Boards of the participating institutions. All subjects 1422 
provided written informed consent. 1423 
Rietschel, M; Nöthen, MM; Schulze, TG; Bauer, M; Forstner, AJ; Müller-Myhsok, B | 1424 
24618891 | BOMA-Germany III | bip_bmg3_eur 1425 
Cases were recruited at the Central Institute of Mental Health in Mannheim, University of 1426 
Heidelberg, and other collaborating psychiatric hospitals in Germany.  All cases received a lifetime 1427 
diagnosis of BD according to the DSM-IV criteria using a consensus best-estimate procedure based 1428 
 52 
on all available information including structured diagnostic interviews using the AMDP, 1429 
Composite International Diagnostic Screener (CID-S), SADS-L and/or SCID, medical records, 1430 
and the family history method. In addition, the OPCRIT system was used for the detailed 1431 
polydiagnostic documentation of symptoms. Controls were selected randomly from a Munich-1432 
based community sample and recruited at the Max-Planck Institute of Psychiatry. They were 1433 
screened for the presence of anxiety and mood disorders using the CID-S. Only individuals without 1434 
mood and anxiety disorders were collected as controls. Study protocols were reviewed and 1435 
approved in advance by Institutional Review Boards of the participating institutions. All subjects 1436 
provided written informed consent. 1437 
Hauser, J; Lissowska, J; Forstner, AJ | 24618891 | BOMA-Poland | bip_bmpo_eur 1438 
Cases were recruited at the Department of Psychiatry, Poznan University of Medical Sciences, 1439 
Poznan, Poland. All cases received a lifetime diagnosis of BD according to the DSM-IV criteria 1440 
on the basis of a consensus best-estimate procedure and structured diagnostic interviews using the 1441 
SCID. Controls were drawn from a population-based case-control sample recruited by the Cancer-1442 
Center and Institute of Oncology, Warsaw, Poland and a hospital-based case-control sample 1443 
recruited by the Nofer Institute of Occupational Medicine, Lodz, Poland. The Polish controls were 1444 
produced by the International Agency for Research on Cancer (IARC) and the Centre National de 1445 
Génotypage (CNG) GWAS Initiative for a study of upper aerodigestive tract cancers. The controls 1446 
were not screened for a history of mental illness. Study protocols were reviewed and approved in 1447 
advance by Institutional Review Boards of the participating institutions. All subjects provided 1448 
written informed consent. 1449 
Rietschel, M; Nöthen, MM; Rivas, F; Mayoral, F; Kogevinas, M; others | 24618891 | BOMA-1450 
Spain | bip_bmsp_eur 1451 
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Cases were recruited at the mental health departments of the following five centers in Andalusia, 1452 
Spain: University Hospital Reina Sofia of Córdoba, Provincial Hospital of Jaen; Hospital of Jerez 1453 
de la Frontera (Cádiz); Hospital of Puerto Real (Cádiz); Hospital Punta Europa of Algeciras 1454 
(Cádiz); and Hospital Universitario San Cecilio (Granada). Diagnostic assessment was performed 1455 
using the SADS-L; the OPCRIT; a review of medical records; and interviews with first and/or 1456 
second degree family members using the Family Informant Schedule and Criteria (FISC). 1457 
Consensus best estimate BD diagnoses were assigned by two or more independent senior 1458 
psychiatrists and/or psychologists, and according to the RDC, and the DSM-IV. Controls were 1459 
Spanish subjects drawn from a cohort of individuals recruited in the framework of the European 1460 
Community Respiratory Health Survey (ECRHS, http://www.ecrhs.org/). The controls were not 1461 
screened for a history of mental illness. Study protocols were reviewed and approved in advance 1462 
by Institutional Review Boards of the participating institutions. All subjects provided written 1463 
informed consent. 1464 
Fullerton, J.M.; Mitchell, P.B.; Schofield, P.R.; Martin N.G.; Cichon, S. | 24618891 | BOMA-1465 
Australia | bip_bmau_eur 1466 
Cases were recruited at the Mood Disorder Unit, Prince of Wales Hospital in Sydney. All cases 1467 
received a lifetime diagnosis of BD according to the DSM-IV criteria on the basis of a consensus 1468 
best-estimate procedure and structured diagnostic interviews using the DIGS, FIGS, and the SCID. 1469 
Controls were parents of unselected adolescent twins from the Brisbane Longitudinal Twin Study. 1470 
The controls were not screened for a history of mental illness. Study protocols were reviewed and 1471 
approved in advance by Institutional Review Boards of the participating institutions. All subjects 1472 
provided written informed consent. 1473 
Grigoroiu-Serbanescu, M; Nöthen, MM | 21353194 | BOMA-Romania | bip_rom3_eur 1474 
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Cases were recruited from consecutive admissions to the Obregia Clinical Psychiatric Hospital, 1475 
Bucharest. Patients were administered the DIGS and FIGS interviews. Information was also 1476 
obtained from medical records and close relatives. The diagnosis of BP-I was assigned according 1477 
to DSM-IV criteria using the best estimate procedure.  All patients had at least two hospitalized 1478 
illness episodes. Population-based controls were evaluated using the DIGS to exclude a lifetime 1479 
history of major affective disorders, schizophrenia, schizoaffective disorders, and other psychoses, 1480 
obsessive-compulsive disorder, eating disorders, and alcohol or drug addiction. 1481 
Craddock, N, Jones, I, Jones, L | 17554300 | WTCCC | bip_wtcc_eur_sr-qc 1482 
Cases were all over the age of 17 yr, living in the UK and of European descent. Recruitment was 1483 
undertaken throughout the UK and included individuals who had been in contact with mental 1484 
health services and had a lifetime history of high mood. After providing written informed consent, 1485 
participants were interviewed by a trained psychologist or psychiatrist using a semi-structured 1486 
lifetime diagnostic psychiatric interview (Schedules for Clinical Assessment in Neuropsychiatry) 1487 
and available psychiatric medical records were reviewed. Using all available data, best-estimate 1488 
life-time diagnoses were made according to the RDC. In the current study we included cases with 1489 
a lifetime diagnosis of RDC bipolar 1 disorder, bipolar 2 disorder or schizo-affective disorder, 1490 
bipolar type. Controls were recruited from two sources: the 1958 Birth Cohort study and the UK 1491 
Blood Service (blood donors) and were not screened for history of mental illness. All cases and 1492 
controls were recruited under protocols approved by the appropriate IRBs. All subjects gave 1493 
written informed consent. 1494 
Kelsoe, J | 21926972 [PGC1] | USA (GAIN) | bip_gain_eur 1495 
Genetic Association Information Network (GAIN)/ The Bipolar Genome Study (BiGS) The BD 1496 
sample was collected under the auspices of the NIMH Genetics Initiative for BD 1497 
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(http://zork.wustl.edu/nimh/), genotyped as part of GAIN and analyzed as part of a larger GWAS 1498 
conducted by the BiGS consortium. Approximately half of the GAIN sample was collected as 1499 
multiplex families or sib pair families (waves 1-4), the remainder were collected as individual 1500 
cases (wave 5). Subjects were ascertained at 11 sites: Indiana University, John Hopkins University, 1501 
the NIMH Intramural Research Program, Washington University at St. Louis, University of 1502 
Pennsylvania, University of Chicago, Rush Medical School, University of Iowa, University of 1503 
California, San Diego, University of California, San Francisco, and University of Michigan. All 1504 
investigations were carried out after the review of protocols by the IRB at each participating 1505 
institution. At all sites, potential cases were identified from screening admissions to local treatment 1506 
facilities and through publicity programs or advocacy groups. Potential cases were evaluated using 1507 
the DIGS, FIGS, and information from relatives and medical records. All information was 1508 
reviewed through a best estimate diagnostic procedure by two independent and non-interviewing 1509 
clinicians and a consensus best-estimate diagnosis was reached. In the event of a disagreement, a 1510 
third review was done to break the tie. Controls were from the NIMH Genetic Repository sample 1511 
obtained by Dr. P. Gejman through a contract to Knowledge Networks, Inc.  Only individuals with 1512 
complete or near-complete psychiatric questionnaire data who did not fulfill diagnostic criteria for 1513 
major depression and denied a history of psychosis or BD were included as controls for BiGS 1514 
analyses.  Controls were matched for gender and ethnicity to the cases. 1515 
Kelsoe, J; Sklar, P; Smoller, J | [PGC1 Replication] | USA (FAT2; FaST, BiGS, TGEN) | 1516 
bip_fat2_eur 1517 
Cases were collected from individuals at the 11 U.S. sites described for the GAIN sample.  Eligible 1518 
participants were age 18 or older meeting DSM-IV criteria for BD-I or BD-II by consensus 1519 
diagnosis based on interviews with the Affective Disorders Evaluation (ADE) and MINI. All 1520 
 56 
participants provided written informed consent and the study protocol was approved by IRBs at 1521 
each site. Collection of phenotypic data and DNA samples were supported by NIMH grants 1522 
MH063445 (JW Smoller); MH067288 (PI: P Sklar), and MH63420 (PI: V Nimgaonkar). The 1523 
control samples were NIMH controls that were using the methods described in that section. The 1524 
case and control samples were independent of those included in the GAIN sample. 1525 
Kirov, G | 25055870 | Bulgarian trios | bip_butr_eur 1526 
All cases were recruited in Bulgaria from psychiatric inpatient and outpatient services. Each 1527 
proband had a history of hospitalisation and was interviewed with an abbreviated version of the 1528 
SCAN. Consensus best-estimate diagnoses were made according to DSM-IV criteria by two 1529 
researchers. All participants gave written informed consent and the study was approved by local 1530 
ethics committees at the participating centers. 1531 
Kirov, G | 25055870 | UK trios | bip_uktr_eur 1532 
The BD subjects were recruited from lithium clinics and interviewed in person by a senior 1533 
psychiatrist, using abbreviated version of the SCAN. Consensus best-estimate diagnoses were 1534 
made based on the interview and hospital notes. Ethics committee approval for the study was 1535 
obtained from the relevant research ethics committees and all individuals provided written 1536 
informed consent for participation. 1537 
Landén, M; Sullivan, PF; Sklar, P | [ICCBD] | Sweden (ICCBD) | bip_swa2_eur 1538 
The BD subjects were identified using the Swedish National Quality Register for Bipolar Disorders 1539 
(BipoläR) and the Swedish National Patient Register (using a validated algorithm requiring at least 1540 
two hospitalizations with a BD diagnosis). A confirmatory telephone interview with a diagnostic 1541 
review was conducted. Additional subjects were recruited from the St. Göran Bipolar Project 1542 
(Affective Center at Northern Stockholm Psychiatry Clinic, Sweden), enrolling new and ongoing 1543 
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patients diagnosed with BD using structured clinical interviews. Diagnoses were made according 1544 
to the DSM-IV criteria (BipoläR and St. Göran Bipolar Project) and ICD-10 (National Patient 1545 
Register). The control subjects used were the same as for the SCZ analyses described above. All 1546 
ascertainment procedures were approved by the Regional Ethical Committees in Sweden. 1547 
Landén, M; Sullivan, PF; Sklar, P | [ICCBD] | Sweden (ICCBD) | bip_swei_eur 1548 
The cases and controls in the bip_swei_eur sample were recruited using the same ascertainment 1549 
methods described for the bip_swa2_eur sample. 1550 
Leboyer, M | [PGC1 replication] | France | bip_fran_eur 1551 
Cases with BD1 or BD2 and control samples were recruited as part of a large study of genetics of 1552 
BD in France (Paris-Creteil, Bordeaux, Nancy) with a protocol approved by relevant IRBs and 1553 
with written informed consent. Cases were of French descent for more than 3 generations were 1554 
assessed by a trained psychiatrist or psychologist using structured interviews supplemented by 1555 
medical case notes, mood scales and self-rating questionnaire assessing dimensions. 1556 
Li, Q | 24166486; 27769005 | USA (Janssen), SAGE controls | bip_jst5_eur 1557 
The study included unrelated patients with bipolar 1 disorder from 6 clinical trials (IDs: 1558 
NCT00253162, NCT00257075, NCT00076115, NCT00299715, NCT00309699, and 1559 
NCT00309686). Participant recruitment was conducted by Janssen Research & Development, 1560 
LLC (formerly known as Johnson & Johnson Pharmaceutical Research & Development, LLC) to 1561 
assess the efficacy and safety of risperidone. Bipolar cases were diagnosed according to DSM-IV-1562 
TR criteria. The diagnosis of bipolar disorder was confirmed by the Schedule for Affective 1563 
Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-1564 
PL) in NCT00076115, by the SCID in NCT00257075 and NCT00253162, or by the MINI in 1565 
NCT00299715 and NCT00309699, and NCT00309686, respectively. Additional detailed 1566 
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descriptions of these clinical trials can be found at ClinicalTrials.gov. Only patients of European 1567 
ancestry with matching controls were included in the current analysis. Controls subjects were 1568 
drawn from the Study of Addiction: Genetics and Environment (SAGE, dbGaP Study Accession: 1569 
phs000092.v1.p1). Control subjects did not have alcohol dependence or drug dependence 1570 
diagnoses; however, mood disorders were not an exclusion criterion. 1571 
McQuillin, A; Gurling, H | 18317468 [PGC1] | UCL (University College London), London, 1572 
UK | bip_uclo_eur 1573 
The UCL sample comprised Caucasian individuals who were ascertained and received clinical 1574 
diagnoses of bipolar 1 disorder according to UK National Health Service (NHS) psychiatrists at 1575 
interview using the categories of the International Classification of Disease version 10. In addition 1576 
bipolar subjects were included only if both parents were of English, Irish, Welsh or Scottish 1577 
descent and if three out of four grandparents were of the same descent. All volunteers read an 1578 
information sheet approved by the Metropolitan Medical Research Ethics Committee who also 1579 
approved the project for all NHS hospitals. Written informed consent was obtained from each 1580 
volunteer. The UCL control subjects were recruited from London branches of the National Blood 1581 
Service, from local NHS family doctor clinics and from university student volunteers. All control 1582 
subjects were interviewed with the SADS-L to exclude all psychiatric disorders. 1583 
Craddock, N; Jones, I; Jones, L | [ICCBD] | Cardiff and Worcester, UK (ICCBD-BDRN) | 1584 
bip_icuk_eur 1585 
Cases were all over the age of 17 yr, living in the UK and of European descent. Cases were 1586 
recruited via systematic and not systematic methods as part of the Bipolar Disorder Research 1587 
Network project (www.bdrn.org),  provided written informed consent and  were interviewed using 1588 
a semi-structured diagnostic interview, the Schedules for Clinical Assessment in Neuropsychiatry. 1589 
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Based on the information gathered from the interview and case notes review, best-estimate lifetime 1590 
diagnosis was made according to DSM-IV. Inter-rater reliability was formally assessed using 20 1591 
randomly selected cases (mean ĸ Statistic = 0.85).  In the current study we included cases with a 1592 
lifetime diagnosis of DSM-IV bipolar disorder or schizo-affective disorder, bipolar type. The 1593 
BDRN study has UK National Health Service (NHS) Research Ethics Committee approval and 1594 
local Research and Development approval in all participating NHS Trusts/Health Boards.Controls 1595 
were part of the Wellcome Trust Case Control Consortium common control set, which comprised 1596 
healthy blood donors recruited from the UK Blood Service and samples from the 1958 British 1597 
Birth Cohort. Controls were not screened for a history of mental illness. All cases and controls 1598 
were recruited under protocols approved by the appropriate IRBs. All subjects gave written 1599 
informed consent. 1600 
Ophoff, RA | Not Published | Netherlands | bip_ucla_eur 1601 
The case sample consisted of inpatients and outpatients recruited through psychiatric hospitals and 1602 
institutions throughout the Netherlands. Cases with DSM-IV bipolar disorder, determined after 1603 
interview with the SCID, were included in the analysis. Controls were collected in parallel at 1604 
different sites in the Netherlands and were volunteers with no psychiatric history after screening 1605 
with the (MINI). Ethical approval was provided by UCLA and local ethics committees and all 1606 
participants gave written informed consent.  1607 
Paciga, S | [PGC1] | USA (Pfizer) | bip_pf1e_eur  1608 
This sample comprised Caucasian individuals recruited into one of three Geodon (ziprasidone) 1609 
clinical trials (NCT00141271, NCT00282464, NCT00483548). Subjects were diagnosed by a 1610 
clinician with a primary diagnosis of Bipolar 1 Disorder, most recent episode depressed, with or 1611 
without rapid cycling, without psychotic features, as defined in the DSM-IV-TR (296.5x) and 1612 
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confirmed by the MINI (version 5.0.0).  Subjects also were assessed as having a HAM-D-17 total 1613 
score of >20 at the screening visit.  The trials were conducted in accordance with the protocols, 1614 
International Conference on Harmonization of Good Clinical Practice Guidelines, and applicable 1615 
local regulatory requirements and laws. Patients gave written informed consent for the collection 1616 
of blood samples for DNA for use in genetic studies. 1617 
Pato, C | [ICCBD] | Los Angeles, USA (ICCBD-GPC)| bip_usc2_eur 1618 
Genomic Psychiatry Consortium (GPC) cases and controls were collected via the University of 1619 
Southern California healthcare system, as previously described. Using a combination of focused, 1620 
direct interviews and data extraction from medical records, diagnoses were established using the 1621 
OPCRIT and were based on DSM-IV-TR criteria. Age and gender-matched controls were 1622 
ascertained from the University of Southern California health system and assessed using a 1623 
validated screening instrument and medical records. 1624 
Scott, L; Myer, RM; Boehnke, M | 19416921 [PGC1] | Michigan, USA (Pritzker and NIMH) 1625 
| bip_mich_eur 1626 
The Pritzker Neuropsychiatric Disorders Research Consortium (NIMH/Pritzker) case and controls 1627 
samples were from the NIMH Genetics Initiative Genetics Initiative Repository. Cases were 1628 
diagnosed according to DMS-III or DSM-IV criteria using diagnostic interviews and/or medical 1629 
record review. Cases with low confidence diagnoses were excluded. From each wave 1-5 available 1630 
non-Ashkenazi European-origin family, two BD1 siblings were included when possible and the 1631 
proband was preferentially included if available (n=946 individuals in 473 sibling pairs); otherwise 1632 
a single BD1 case was included (n=184). The bipolar sibling pairs were retained within the 1633 
NIMH/Pritzker sample when individuals in more than one study were uniquely assigned to a study 1634 
set. Controls had non-Ashkenazi European-origin, were aged 20-70 years and reported no 1635 
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diagnosis with or treatment for BD or schizophrenia, and that they had not heard voices that others 1636 
could not hear. Individuals with suspected major depression were excluded based on answers to 1637 
questions related to depressive mood. NIMH controls were further selected as the best match(es) 1638 
to NIMH cases based on self-reported ancestry. 1639 
Sklar, P; Smoller, J | 18317468 [PGC1] | USA (STEP1) | bip_stp1_eur 1640 
The Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) was a seven-1641 
site, national U.S., longitudinal cohort study designed to examine the effectiveness of treatments 1642 
and their impact on the course of BD that enrolled 4,361 participants who met DSM-IV criteria 1643 
for BD1, BD2, bipolar not otherwise specified (NOS), schizoaffective manic or bipolar type, or 1644 
cyclothymic disorder based on diagnostic interviews. From the parent study, 2,089 individuals 1645 
who were over 18 years of age with BD1 and BD2 diagnoses consented to the collection of blood 1646 
samples for DNA. BD samples with a consensus diagnosis of BD1 were selected for inclusion in 1647 
STEP1. Two groups of controls samples from the NIMH repository were used. One comprised 1648 
DNA samples derived from US Caucasian anonymous cord blood donors.  The second were 1649 
controls who completed the online self-administered psychiatric screen and were ascertained as 1650 
described above, by Knowledge Networks Inc.  For the second sample of controls only those 1651 
without history of schizophrenia, psychosis, BD or major depression with functional impairment 1652 
were used. 1653 
Sklar, P; Smoller, J | 18711365 [PGC1] | USA (STEP2) | bip_stp2_eur 1654 
The STEP2 sample included BD-1 and BD-2 samples from the STEP-BD study described above 1655 
along with BD-2 subjects from UCL study also described above. The controls samples for this 1656 
study were from the NIMH repository as described above for the STEP1 study. 1657 
 1658 
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European ancestry, trio design 1659 
Schizophrenia  1660 
Kirov, G: Owen M | 22083728| Bulgaria | ms.scz_butr_eur  1661 
Families from Bulgaria were recruited if a proband had schizophrenia or schizoaffective disorder, 1662 
both parents were available, and all members of the trio agreed to participate in the study. 1663 
Recruitment took place between 1999 and 2004 in several psychiatric hospitals in Bulgaria. Ethical 1664 
Committee approval was obtained from each of these hospitals. All probands and all parents 1665 
received an Information Sheet and signed Informed Consent Forms. All participants had attended 1666 
mainstream schools, which at the time in Bulgaria, excluded people with mental retardation. 1667 
Probands were either in- or out-patients at the time of the study but each had a history of 1668 
hospitalization. A team of psychiatrists was trained in using the rating scales and methods of the 1669 
study. We used the SCAN instrument to perform an interview for psychotic and mood symptoms. 1670 
This instrument has been translated into Bulgarian and validated by one of its authors (A. 1671 
Jablensky). Consensus diagnoses were made according to DSM-IV criteria on the basis of an 1672 
interview and inspection of hospital notes by two clinicians. If consensus was not attained, the 1673 
patient was re-interviewed by a research interview trained clinician and was excluded if consensus 1674 
could still not be reached. In addition, approximately 23% of the sample was selected at random 1675 
and re-interviewed by a research interview trained clinician. Hospital notes were also collected for 1676 
affected relatives in order to confirm diagnoses.  1677 
Levinson, D | 22885689 | Six countries | ms.scz_lemu_eur  1678 
Schizophrenia cases were included from the family sample of European-ancestry pedigrees 1679 
described by Levinson et al. Participants and their families in this trio study, probands were 1680 
ascertained and recruited from different clinical settings (e.g. inpatients, outpatients and 1681 
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community facilities) in six countries (Australia, France, Germany, Ireland, UK, and the US).  1682 
(Unrelated individuals were included as part of a case-control design, see Levinson, D, 1683 
scz_lacw_eur above.) Diagnoses were established using semi-structured interviews, psychiatric 1684 
records and informant reports. Case probands were diagnosed with schizophrenia or 1685 
schizoaffective disorder according to DSM-III-R criteria. The trio-based analysis included families 1686 
where there was at least one affected proband and two available parents. Each affected sibling in 1687 
such families was included, with the parents, as an independent trio. All protocols were approved 1688 
by loci IRBs, and all cases provided written informed consent.  1689 
Kirov, G: Owen, M | Not Published | Bulgaria | ms.scz_uktr_eur  1690 
All cases and parents were recruited from UK and had a history of hospitalization for treatment of 1691 
schizophrenia. Diagnosis was confirmed following a SCAN interview and review of case notes 1692 
followed by consensus diagnosis according to DSM-IV criteria. The samples were genotyped at 1693 
the Broad Institute. All participants gave written informed consent and the study was approved by 1694 
local ethics committees at the participating centers. The samples were genotyped at the Broad 1695 
Institute.  1696 
 1697 
Genotype Quality Control 1698 
To ensure independence of the data sets, individuals were excluded until no individual showed a 1699 
relatedness (pihat) value greater than 0.2 to any other individual in the collection, while 1700 
preferentially keeping the case over the control for case-control related pairs. In total 1,795 BD 1701 
cases, 1,165 SCZ cases and 27,274 controls were removed (most of which were previously 1702 
known), leaving 20,129 BD cases 33,426 SCZ cases and 54,065 controls for the final meta-1703 
analysis.  1704 
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For analyses directly comparing BD and SCZ, we matched cases from both phenotypes on 1705 
genotyping platform and ancestry, resulting in 15,270 BD cases versus 23,585 SCZ cases. Hence, 1706 
we were able to match 76% of BD cases and 71% of SCZ cases for this case vs case analysis.  1707 
Among our entire dataset, 44% of the sample was female, 51% was male and 5% were unreported 1708 
by the collection site. This work focused explicitly on the autosomes and sought maximal power 1709 
across the analyses, sex was not used except for during quality control and sex-specific analyses 1710 
were not performed in this effort. Individual ages were not provided. For a subset of cases, we had 1711 
information for age of onset which were used in subphenotype specific analyses only. 1712 
 1713 
Sub-phenotype Description 1714 
BD sub-phenotypes were collected by each study site using a combination of diagnostic 1715 
instruments, case records and participant interviews. Ascertainment details for each study site are 1716 
described in the supplementary data of the PGC Bipolar Working Group paper(Stahl et al., 2017). 1717 
The selection of phenotypes for collection by this group was determined by literature searches in 1718 
order to determine phenotypes with prior evidence for heritability. It was further refined dependent 1719 
on the availability of phenotype data across a range of study sites and the consistency by which 1720 
the phenotypes were defined. Schizophrenia subphenotypes represent quantitative traits extracted 1721 
using factor analysis from a set of standard psychiatric assessments and represent four symptom 1722 
dimensions (manic, depressive, positive and negative). These subphenotypes were used 1723 
previously(Ruderfer et al., 2014) but in this work we have increased the sample size with additional 1724 
cohorts being added. 1725 
 1726 
METHOD DETAILS 1727 
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 1728 
QUANTIFICATION AND STATISTICAL ANALYSIS  1729 
  1730 
Quality Control, Imputation, Association Analysis and Polygenic Risk Score Testing 1731 
Quality control and imputation were performed on each of the study cohort datasets (n=81), 1732 
according to standards established by the Psychiatric Genomics Consortium (PGC). The quality 1733 
control parameters for retaining SNPs and subjects were: SNP missingness < 0.05 (before sample 1734 
removal); subject missingness (p < 0.02); autosomal heterozygosity deviation (| Fhet | < 0.2); SNP 1735 
missingness < 0.02 (after sample removal); difference in SNP missingness between cases and 1736 
controls < 0.02; and SNP Hardy-Weinberg equilibrium (p > 10−6 in controls or p > 10−10 in cases). 1737 
Genotype imputation was performed using the pre-phasing/imputation stepwise approach 1738 
implemented in IMPUTE2(Howie et al., 2011) / SHAPEIT(Delaneau et al., 2013) (chunk size of 1739 
3 Mb and default parameters). The imputation reference set consisted of 2,186 phased haplotypes 1740 
from the full 1000 Genomes Project dataset (August 2012, 30,069,288 variants, release 1741 
“v3.macGT1”), all variants align to human genome build 19 (hg19). After imputation, we used the 1742 
best guess genotypes (genotype probability > 0.8), for further robust relatedness testing and 1743 
population structure analysis. Here we required very high imputation quality (INFO > 0.8) and low 1744 
missingness (<1%) for further quality control. After linkage disequilibrium (LD) pruning (r2 < 1745 
0.02) and frequency filtering (MAF > 0.05), there were 14,473 autosomal SNPs in the data set. 1746 
Principal component estimation was done with the same collection of autosomal SNPs. We tested 1747 
the first 20 principal components for phenotype association (using logistic regression with study 1748 
indicator variables included as covariates) and evaluated their impact on the genome-wide test 1749 
statistics using λ. Thirteen principal components namely 1,2,3,4,5,6,7,8,10,12,15,18,20 were 1750 
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included in all association analyses (λ=1.45).  Analytical steps were repeated for SCZ vs BD 1751 
analysis. 1752 
We performed four main association analyses (Figure 1), i.e. (i) GWAS of BD and SCZ as a single 1753 
combined case phenotype, as well as disorder-specific GWAS using independent control sets in 1754 
(ii) BD cases vs BD controls and (iii) SCZ cases vs SCZ controls, and (iv) association analysis of 1755 
SCZ cases vs BD cases. For all GWS loci from the GWAS of BD and SCZ vs controls we identified 1756 
any GWS loci within 1Mb from the extent of the locus in the previously published PGC SCZ vs 1757 
controls(Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014) and the 1758 
most recent PGC GWAS of BD vs controls(Stahl et al., 2017) and performed conditional analysis. 1759 
Specifically, we transformed the genotype probabilities of the disease variant into dosages and 1760 
used it as an additional covariate for the association analysis for the BD+SCZ vs controls index 1761 
SNP. This was done within each cohort and an OR based inverse SE weighted meta-analysis was 1762 
performed for the final result. All datasets were included except for those with trios. 1763 
 1764 
Summary-data-based Mendelian Randomization (SMR)  1765 
SMR(Zhu et al., 2016) is a method that integrates summary level GWAS data with gene expression 1766 
quantitative trait loci (eQTL) identified in independent data sets. This integration aims to identify 1767 
variants that have pleotropic effects on expression of a given gene and the phenotype. While 1768 
significant findings may indeed reflect a causal path from variant to phenotype through expression, 1769 
it is impossible to discern statistically between pleiotropy and causality. However, the method can 1770 
remove linkage as driving the result, and uses the data available to prioritise amongst genes in 1771 
genomic regions that show association with disease. We used SMR as a statistical fine-mapping 1772 
tool applied to the SCZ vs BD GWAS results to identify loci with strong evidence of causality via 1773 
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gene expression. SMR analysis is limited to significant (FDR < 0.05) cis SNP-expression 1774 
quantitative trait loci (eQTLs) with MAF > 0.01. eQTLs passing these thresholds were combined 1775 
with GWAS results in the SMR test, with significance (pSMR) reported at a Bonferroni-corrected 1776 
threshold for each eQTL data set. The eQTL architecture may differ between genes. For example, 1777 
through LD, many SNPs can generate significant associations with the same gene, but in some 1778 
instances multiple SNPs may be independently associated with the expression of a gene. After 1779 
identification of significant SNP-expression-trait association through the SMR test, a follow-up 1780 
heterogeneity test aims to prioritize variants by excluding regions for which there is conservative 1781 
evidence for multiple causal loci (pHET < 0.05). SMR analyses were conducted using eQTL data 1782 
from whole peripheral blood(Westra et al., 2013), dorsolateral prefrontal cortex generated by the 1783 
CommonMind Consortium8, and 11 brain sub-regions from the GTEx consortium(Consortium, 1784 
2015).  1785 
 1786 
Regional joint GWAS  1787 
Summary statistic Z-scores were calculated for each marker in each of the four main GWAS 1788 
results, using the logistic regression coefficient and its standard error. Rare SNPs (MAF < 0.01), 1789 
and SNPs with a low INFO score (< 0.3) in either dataset were removed. The causal variant 1790 
relationships between SCZ and BD were investigated using the Bayesian method software pw-1791 
gwas (v0.2.1), with quasi-independent regions determined by estimate LD blocks in an analysis of 1792 
European individuals (n=1,703)(Berisa and Pickrell, 2015; Pickrell et al., 2016). Briefly, pw-gwas 1793 
takes a Bayesian approach to determine the probability of five independent models of association. 1794 
(1) There is no causal variant in BD or SCZ; (2) a causal variant in BD, but not SCZ (3); a causal 1795 
variant in SCZ, but not BD; (4) a shared causal variant influencing both BD and SCZ; (5) two 1796 
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causal variants where one influences BD, and one influences SCZ (Figure 2). The posterior 1797 
probability of each model is calculated using model priors, estimated empirically within pw-gwas. 1798 
Regions were considered to support a particular model when the posterior probability of the model 1799 
was greater than 0.5.  1800 
 1801 
Regional SNP-heritability estimation 1802 
We calculated local SNP-heritability independently for SCZ and BD using the Heritability 1803 
Estimator from Summary Statistics (HESS) software(Shi et al., 2016) for each of the independent 1804 
regions defined above. The sum of these regional estimates is the total SNP-heritability of the trait. 1805 
To calculate local SNP-heritability HESS requires reference LD matrices representative of the 1806 
population from which the GWAS samples were drawn. We utilized the 1000 genomes European 1807 
individuals as the reference panel(The 1000 Genomes Project Consortium, 2015). Unlike pw-1808 
gwas(Pickrell et al., 2016), HESS does not assume that only one causal variant can be present in 1809 
each region. 1810 
 1811 
DATA AND SOFTWARE AVAILABILITY  1812 
Summary statistics from GWAS are publically available at https://www.med.unc.edu/pgc/results-1813 
and-downloads/downloads. 1814 
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